Document:

QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.2  

        CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.R.F §§ 200.80(B)4 AND 240.24B-2 

Elan License Agreement

Execution Copy (V9)

24 October 2002  

 
 

AMENDED AND RESTATED
  LICENSE AGREEMENT    
    
    BY AND BETWEEN    
    
    ORASENSE LTD
  A Bermuda Limited Company    
    
    ISIS PHARMACEUTICALS, INC
  A Delaware Corporation

    
    AND    
    
    ELAN CORPORATION, PLC
  A Public Irish Company    
    
    October 24, 2002    

   TABLE OF CONTENTS  

	CLAUSE
 
	 	HEADING
	 	PAGE

	1	 	DEFINITIONS; INTERPRETATION	 	3
	

2	
 	

GRANT OF RIGHTS	
 	

7
	

3	
 	

SUBLICENSES	
 	

8
	

4	
 	

DEVELOPMENT OF ROYALTY PRODUCT	
 	

8
	

5	
 	

REGULATORY APPROVALS	
 	

9
	

6	
 	

FINANCIAL PROVISIONS	
 	

9
	

7	
 	

CONFIDENTIAL INFORMATION	
 	

11
	

8	
 	

WARRANTIES AND INDEMNITIES	
 	

12
	

9	
 	

INTELLECTUAL PROPERTY OWNERSHIP RIGHTS	
 	

15
	

10	
 	

RIGHTS EXPLOITATION OUTSIDE THE FIELD	
 	

16
	

11	
 	

NON-COMPETITION	
 	

16
	

12	
 	

TERM AND TERMINATION OF AGREEMENT	
 	

16
	

13	
 	

FORCE MAJEURE	
 	

18
	

14	
 	

SETTLEMENT OF DISPUTES; GOVERNING LAW	
 	

18
	

15	
 	

ASSIGNMENT	
 	

18
	

16	
 	

NOTICES	
 	

19
	

17	
 	

MISCELLANEOUS CLAUSES	
 	

20

2

   
        AMENDED AND RESTATED LICENSE AGREEMENT made this 24th day of October, 2002 among Elan Corporation, plc, Orasense Ltd.
a Bermuda limited company, and Isis Pharmaceuticals, Inc., a Delaware corporation. 

RECITALS:  

        A.    Contemporaneously
herewith, Elan, EIS, Orasense and Isis (capitalized terms used herein are defined below) are entering into the Development Agreement for the purpose of
amending, restating and recording the terms and conditions of a joint venture and of regulating their relationship with each other and certain aspects of the affairs of and their dealings with
Orasense. 

        B.    Elan
is beneficially entitled to the use of certain know-how and certain patents that have been granted or are pending in relation to the development and
production of various drug delivery technologies and drug products. 

        C.    Orasense
desires to enter into this Agreement with Elan so as to permit Orasense to utilize the Elan Intellectual Property in the research, development, manufacture,
distribution and sale of Products in the Field and in the Territory. 

        D.    Orasense
and Elan entered into that certain License Agreement (the "Original License Agreement") dated April 20, 1999 (the "Original Effective Date"). The Parties
now wish to amend, restate and supercede the Original License Agreement with this Agreement. 

        NOW THEREFORE, IT IS HEREBY AGREED AS FOLLOWS: 

	1.
	DEFINITIONS; INTERPRETATION

        A.    Definitions.    In this Agreement, the following definitions shall apply: 

        1.1.    "Affiliate"
shall mean, with respect to Isis or Elan, any corporation or entity other than Orasense (and entities controlled by it) controlling,
controlled or under the common control of Isis or Elan, as the case may be, and, with respect to Orasense, any corporation or entity under control of Orasense, but excluding, in the case of Elan, an
Elan JV. A corporation or non-corporate entity shall be regarded as in control of another corporation if it owns or directly or indirectly controls at least fifty percent (50%) of the
voting stock of the other corporation or (a) in the absence of the ownership of at least fifty percent (50%) of the voting stock of a corporation or (b) in the case of a
non-corporate entity, the power to direct or cause the direction of the management and policies of such corporation or non-corporate entity, as applicable. 

        1.2.    "Agreement"
shall mean this agreement (which expression shall be deemed to include the Recitals and the Schedules hereto); 

        1.3.    "cGCP",
"cGLP" and "cGMP" shall mean current Good Clinical Practices, current Good Laboratory Practices and current Good Manufacturing Practices
respectively; 

        1.4.    "Commercialization"
shall mean the manufacture, promotion, distribution, marketing and sale of the Products; 

        1.5.    "Control"
shall mean the ability of a Party to grant a license or sublicense as contemplated herein without having to obtain the prior consent of any
third party or having to amend any agreement between such Party and a third party; 

        1.6.    "Cost
of Living Increase" shall mean, with respect to any year of the Term, any increase in the Consumer Price Index published by the Bureau of Labor
Statistics of the United States Department of Labor, All Urban Consumers, United States City Average, All Items (1982-84=100); 

3

 

        1.7.    "Development
Agreement" shall mean the Amended and Restated Joint Development and Operating Agreement of even date entered into among Elan, Isis, EIS and
Orasense; 

        1.8.    "Development
Candidate" shall mean ISIS 104838, [***] of TNF-a, as more
specifically detailed in Exhibit A hereto; 

        1.9.    "Development
Product" shall mean any product containing as an active ingredient the Development Candidate formulated using the Oral Platform for humans; 

        1.10.  "Effective
Date" shall mean the date of execution and delivery of this Agreement; 

        1.11.  "EIS"
shall mean Elan International Services, Ltd., a Bermuda limited company; 

        1.12.  "Elan"
shall mean Elan Corporation, plc, a public limited company incorporated under the laws of Ireland, its, successors and permitted assigns; 

        1.13.  "Elan
Intellectual Property" shall mean (a) the Patents set forth in Schedule 1 hereof; and (b) Know-How Controlled by
Elan that is necessary to practice within the Field. For the avoidance of doubt, Elan Intellectual Property shall not [***] 

        1.14.  "Elan
JV" shall mean an entity that Elan and a third party (i) establish or have established; (ii) take shareholdings in or have a right to
take shareholdings in; and (iii) grant certain licenses in and to certain intellectual property rights for the purpose of implementing a strategic alliance; 

        1.15.  "Elan
License" shall have the meaning set forth in Clause 2.1; 

        1.16.  "Elan
License Agreement" shall mean this Agreement; 

        1.17.  "FDA"
shall mean the United States Food and Drug Administration or any successors or agency the approval of which is necessary to market a product in the
United States of America; 

        1.18.  "Field"
shall mean the research, development and Commercialization of the Oral Platform for use with Oligonucleotide Drugs; 

        1.19.  "Full
Time Equivalent Rate" shall mean, for services proposed to be rendered by Elan, [***] 

        1.20.  "Independent
Third Party" shall mean any person other than Orasense, Elan, Isis or any of their respective Affiliates; 

        1.21.  "Isis"
shall mean Isis Pharmaceuticals, Inc., a Delaware corporation, its successors and permitted assigns; 

        1.22.  "Isis
Delivery Technology" shall have the meaning set forth in the Isis License Agreement; 

        1.23.  "Isis
Development Candidate Technology" shall have the meaning set forth in the Isis License Agreement; 

        1.24.  "Isis
Intellectual Property" shall have the meaning set forth in the Isis License Agreement. 

        1.25.  "Isis
License" shall have the meaning set forth in the Isis License Agreement 

        1.26.  "Isis
License Agreement" shall mean that certain amended and restated license agreement between Isis, Orasense and Elan of even date herewith; 

        1.27.  "Know-How"
shall mean any and all rights to any discovery, invention (whether or not patentable), know-how, substances, data,
techniques, processes, systems, formulations and designs, which is not generally known to the public; 

        1.28.  "Label",
"Labeled" or "Labeling" shall mean all labels and other written, printed or graphic matter upon (i) the Product or any container or
wrapper utilized with the Product, or (ii) any written material accompanying the Product, including, without limitation, package inserts; 

4

 

        1.29.  "Licensed
Technologies" shall mean the Elan Intellectual Property and the Isis Intellectual Property; 

        1.30.  "Licenses"
shall mean the Elan License and the Isis License; 

        1.31.  "Lien"
shall mean any and all liens, security interests, restrictions, claims, encumbrances or rights of third parties of every kind and nature; 

        1.32.  "Management
Committee" shall have the meaning given to such term in the Development Agreement; 

        1.33.  "Marketing
Authorization" shall mean any and all consents or other authorizations or approvals required from a Regulatory Authority or other governmental
authority to Commercialize a pharmaceutical product in a country in the Territory; 

        1.34.  "Net
Sales" shall mean, [***] 

        1.35.  "Oligonucleotide
Drug" shall mean any single stranded [***] at physiological pH oligonucleotide including those
[***] used as a human therapeutic and/or prophylactic compound containing between [***] nucleotides and/or nucleosides including oligonucleotide analogs
which may include [***]. For purposes of this agreement, Oligonucleotide Drug shall specifically exclude oligonucleotides used [***] oligonucleotides
used as [***] an oligonucleotide, oligonucleotides used as [***] or oligonucleotides used as [***]; 

        1.36.  "Oral
Platform" shall mean formulation and excipient systems and technologies [***] which use [***] to
develop dosage forms of drugs and deliver said dosage forms to the [***] to achieve a local or systemic therapeutic effect; 

        1.37.  "Orasense"
shall mean Orasense, Ltd., a Bermuda limited company, its successors and permitted assigns; 

        1.38.  "Orasense
Collaboration Intellectual Property" shall mean (a) Know-How Controlled by Orasense through the end of the Research Term,
(b) Patents Controlled by Orasense claiming inventions made on or before the end of the Research Term, and/or (c) inventions and Patents issued thereon developed by Orasense, Isis and/or
Elan on behalf of Orasense (or any third party under contract with Orasense, Isis and/or Elan) or otherwise under the Original Research Plan or the Research Plan. Schedule 2 to this
Agreement shall contain, by way of illustration but not limitation, examples of Orasense Collaboration Intellectual Property. At the end of the Research Term, the Parties shall amend
Schedule 2, as may be necessary. For the avoidance of doubt, Orasense Collaboration Intellectual Property does not include any Patents and Know-How Controlled by Elan or Isis, as
the case may be. 

        1.39.  "Orasense
Intellectual Property" shall mean Orasense Collaboration Intellectual Property and Orasense Post Collaboration Intellectual Property; 

        1.40.  "Orasense
Post-Collaboration Intellectual Property" shall mean (a) Know-How Controlled by Orasense after the end of the
Research Term, (b) Patents Controlled by Orasense claiming inventions made after the end of the Research Term, and/or (c) inventions and Patents issued thereon made by Isis on Orasense's
behalf after a Failure to Fund. For the avoidance of doubt, Orasense Post-Collaboration Intellectual Property does not include any Patents and Know-How Controlled by Elan or
Isis, as the case may be; 

        1.41.  "Original
Research Plan" means the Research and Development Program under that certain Subscription, Joint Development and Operating Agreement between
Elan, EIS, Isis and Orasense dated April 20, 1999; 

5

 

        1.42.  "Package",
"Packaged" and "Packaging" shall mean all primary and secondary packaging components, including, without limitation, cartons, partitions,
shippers or any other like matter used in packaging the Product; 

        1.43.  "Parties"
shall mean Elan, Isis and Orasense and "Party" shall mean Elan, Isis or Orasense; 

        1.44.  "Patents"
shall mean any and all patents and patent applications under the Control of a Party hereto. Patents shall also include all extensions,
continuations, divisionals, patents-of-additions, re-examinations, re-issues, supplementary protection certificates and foreign counterparts of such
patents and patent applications and any patents issuing thereon and extensions of any patents licensed hereunder; 

        1.45.  "Person"
shall mean an individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated
association, joint venture, or other entity of whatever nature; 

        1.46.  "Primary
Royalty Product" shall mean [***] 

        1.47.  "Product"
shall mean any drug under development or developed by or on behalf of Orasense made or formulated using the Isis Delivery Technology, the Elan
Intellectual Property and/or the Orasense Intellectual Property for administration to humans; 

        1.48.  "Regulatory
Application" shall mean a regulatory application or other application (including any supplements or amendments thereto) required to be filed
or filed with a Regulatory Authority in a country in connection with the Commercialization of a pharmaceutical product in such country. 

        1.49.  "Regulatory
Authority" shall mean any regulatory authority outside the United States of America, the approval of which is necessary to market a Product; 

        1.50.  "Research
Plan" shall have the meaning set forth in the Development Agreement; 

        1.51.  "Research
Term" shall mean the period commencing on [***] and continuing through [***], and any extension
thereto by the mutual agreement of Isis and Elan; 

        1.52.  "Royalty
Payment" shall mean a royalty payment made pursuant to Section 6.1.1(b); 

        1.53.  "Royalty
Product" means a Primary Royalty Product and/or a Secondary Royalty Product, as the case may be. 

        1.54.  "Secondary
Royalty Product" shall mean [***] 

        1.55.  "Term"
shall have the meaning set forth in Clause 12 below; 

        1.56.  "Territory"
shall mean all the countries of the world; 

        1.57.  "United
States Dollar" and "US$" shall mean the lawful currency for the time being of the United States of America; 

        B.    Interpretation.    In this Agreement the following shall apply: 

        (1)  The
singular includes the plural and vice versa, the masculine includes the feminine and vice versa. 

        (2)  Any
reference to a Clause or Schedule shall, unless otherwise specifically provided, be to a Clause or Schedule of this Agreement. 

        (3)  The
headings of this Agreement are for ease of reference only and shall not affect its construction or interpretation. 

6

 

	2.
	GRANT OF RIGHTS.

        2.1.    Subject
to the terms and conditions contained herein and, in consideration of the payments specified under Clause 6.1, Elan hereby grants to
Orasense for the Term a non-exclusive license, including the limited right to grant sublicenses pursuant to Clause 3 hereof, in the Field in the Territory to the Elan Intellectual
Property to research, develop, make and have made, offer for sale, sell, import and export the Products (including Royalty Products) and the Oral Platform in the Field, subject to any contractual
obligations of Elan to Independent Third Parties as of the Effective Date and, unless prohibited by the paragraph below titled Non Competition,
contractual obligations to Independent Third Parties that Elan may enter into after the Effective Date (the "Elan License"). 

        2.2.    If
Isis or Orasense reasonably believes that a Patent Controlled by Elan is necessary to practice in the Field and should be included in the Elan License,
then Isis or Orasense, as the case may be, shall send a written request to Elan (with a sufficiently detailed explanation) to amend Schedule 1 so as to include such Patent in the Elan License.
Elan agrees to consider such request in good faith and to promptly respond to Isis or Orasense, as the case may be. If Elan determines that the Patent Controlled by Elan is necessary to practice in
the Field, then Elan, Orasense and Isis, as the case may be, shall, subject to any contractual obligations of Elan or rights of third parties in existence as of the Effective Date or at any time
hereafter, amend Schedule 1 to include such Patent. 

        2.3.    In
the event, the Elan License granted to Orasense hereunder is restricted or limited by any contractual obligations of Elan or rights of any Independent
Third Parties (a) at any time after the Effective Date or (b) as a result of a breach of the noncompetition provision under Clause 11 of the Original License Agreement, Elan shall
use reasonable commercial efforts to exclude or, where
applicable, to minimize any such restriction or limitation. Except as expressly provided herein, all proprietary rights and rights of ownership with respect to the Elan Intellectual Property shall at
all times remain solely with Elan. For the avoidance of doubt, Elan shall not have any obligations to exclude or minimize any restrictions or limitations under any agreement between an Independent
Third Party and Elan entered into prior to the Effective Date, unless such restrictions or limitations arise in connection with a breach by Elan of the noncompetition provision under Clause 11
of the Original License Agreement. 

        To
the extent royalty or other compensation obligations to Independent Third Parties that are payable with respect to Elan Intellectual Property would be triggered by the use or proposed
use of Elan Intellectual Property by Orasense, its Affiliates and/or sublicensees, Elan will inform Orasense and Isis of such royalty or compensation obligation. If Orasense decides to utilize the
Elan Intellectual Property, then Orasense will be responsible for the payment of such royalty or other compensation obligations relating thereto. 

        2.4.    Notwithstanding
anything contained in this Agreement to the contrary, Elan shall have the right, and subject to the paragraph below titled
Non-Competition, to fully exploit and grant licenses and sublicenses with respect to the Elan Intellectual Property. Elan's rights to exploit and grant licenses referred to in the
immediately preceding sentence shall include, without limitation, the right to research, develop, license and Commercialize products. 

        2.5.    Orasense
shall not be permitted to (a) encumber any of its rights under the Elan License, except pursuant to Clause 3 below; (b) 
assign any of its rights under the Elan License or this Agreement, except pursuant to Clause 15 below; and/or (c) subject to Clause 3 below, sublicense any of its rights under the
Elan License. 

        2.6.    Orasense
will use its reasonable commercial endeavors to exploit the Elan Intellectual Property, the Isis Intellectual Property and Orasense Collaboration
Intellectual Property in accordance with this Agreement. Orasense shall employ diligent efforts to research, develop, register, and Commercialize the Product in the Territory. 

7

 

        2.7.    Orasense
and its sublicensees, if any, shall be solely responsible for ensuring that the research, development, manufacture and Commercialization of the
Products within each country of the Territory is strictly in accordance with all legal, regulatory requirements and applicable laws for each country of the Territory. 

        2.8.    When
Packaged, and to the extent permitted by law, a Label shall include an acknowledgement that the Product is made under license from Elan. Such
acknowledgement shall take into consideration all
regulatory requirements and applicable laws in each country of the Territory and Orasense's reasonable commercial requirements. Orasense shall wherever possible give due acknowledgement and
recognition to Elan in all printed promotional and other material regarding the Product such as stating that the Product is under license from Elan and that the applicable Elan Intellectual Property
has been applied to the Products. Orasense shall consult with and obtain the written approval of Elan as to the format and content of any promotional and other material insofar as it relates to a
description of, or other reference to, the application of the Elan Intellectual Property, such approval not to be unreasonably withheld or delayed. The further consent of Elan shall not be required
where the format and content of such materials is substantively similar as the materials previously furnished to and approved in writing by Elan. 

	3.
	SUBLICENSES

        3.1.  Orasense
shall not sublicense any of its rights in or to the Elan Intellectual Property without the prior written consent of Elan, which consent may be withheld by Elan
in its sole discretion; provided, however, that if such a sublicense is in connection with a bona fide drug development or Commercialization agreement ("Sublicense Agreement"), Orasense may so
sublicense all or any part of its rights in and to the Elan Intellectual Property without Elan's consent, subject to the following terms and conditions: 

        3.1.1.  Orasense
will inform Elan of the identity of any sublicensee under a Sublicense Agreement and the nature of such Sublicense Agreement within
60 days of the execution of such Sublicense Agreement; 

        3.1.2.  any
Sublicense Agreement shall require such sublicensee to maintain the confidentiality of all information concerning the Elan Intellectual Property,
such confidentiality obligations to be no less onerous than as set forth in Clause 7 hereof 

        3.1.3.  Orasense
shall remain responsible for all acts and omissions of any sub-licensee, as if they were acts and omissions by Orasense; and 

        3.1.4.  the
rights of any sublicensee (other than Isis) under any permitted Sublicense Agreement in and to the Elan Intellectual Property shall survive the
termination of this Agreement; provided, however, that (i) such sublicense was granted in accordance with this Agreement; and (ii) nothing contained in this Agreement shall prohibit or
restrict Elan from assigning or transferring to a third party or otherwise disposing of any of the Elan Intellectual Property in accordance with Clause 15 below. 

	4.
	DEVELOPMENT OF ROYALTY PRODUCT

        4.1.  Orasense
shall, and shall cause its sublicensees to, diligently pursue the research and development of the Elan Intellectual Property, Isis Intellectual Property and
Orasense Collaboration Intellectual Property and shall use its, and shall cause its sublicensees to use their, commercially reasonable efforts to Commercialize a Royalty Product. 

        4.2.  At
the request of Elan, the Parties will meet, not to exceed two times per year, to exchange [***] 

8

 

	5.
	REGULATORY APPROVALS

        5.1.  Orasense
shall, or shall cause its sublicensees, at its or its sublicensees' sole cost and expense, to file and shall use its reasonable best efforts to prosecute to
approval or cause its sublicensees to prosecute to approval, the Marketing Authorizations for the Products in the Territory. During any Marketing Authorization registration procedure, Orasense shall
keep Elan promptly and fully advised of Orasense's registration activities, progress and procedures with respect to the Elan Intellectual Property and/or Orasense Collaboration Intellectual Property.
Orasense shall, and shall cause its sublicensees to, inform Elan of any writings, dealings and other communications that Orasense and its sublicensees have with the FDA and any other Regulatory
Authority with respect to the information covered by Section 4.2 above. The Parties shall collaborate in relation to obtaining any required approvals, including Regulatory Approval of any
Regulatory Authority in each country in which Commercialization of any Royalty Product is sought for final Labeling. 

        5.2.  Subject
to agreement to the contrary, any and all Marketing Authorizations filed hereunder for Products shall, to the extent owned by Orasense, remain the property of
Orasense, provided that Orasense shall allow Elan access thereto to enable Elan to research, develop and Commercialize any product outside the Field. Orasense shall maintain or cause its sublicensees
to maintain such Marketing Authorizations at its or their own cost and expense. 

        5.3.  Orasense
and Isis shall indemnify and hold harmless Elan, its agents and employees from and against all claims, damages, losses, liabilities and expenses to which Elan,
its agents, and employees may become subject related to or arising out of Orasense's bad faith, negligence or intentional misconduct in connection with the filing or maintenance of the Marketing
Authorizations. 

	6.
	FINANCIAL PROVISIONS

        6.1  In
consideration of the license to the Patents licensed to Orasense by Elan under the Elan License, Orasense shall pay to Elan, the following amounts: 

        6.1.1  Product Fees and Royalties. Payments to Elan with respect to services rendered in connection with the
Development Product and/or the Oral Platform shall be paid as provided in Clause (a); and (ii) net proceeds derived by Orasense, its Affiliates or sublicensees from Products, shall be
allocated as set forth under Clauses (b) and (c). 

        (a)    Development Work.    Research and development work performed during the Research Term pursuant to the Research
Plan contracted by Orasense to Elan shall be payable by Orasense to Elan based on fully burdened actual costs at Elan's Full Time Equivalent Rate, with annual Cost of Living Increases; 

        (b)    Primary Product Royalties.    Orasense will pay Elan a royalty on (i) any [***]
in connection with a Primary Royalty Product, including [***] thereof; and (ii) the [***] of any Primary Royalty Product. Such royalty will equal
[***] No royalties will be due on [***] and 

        (c)    Secondary Product Royalties.    Orasense will pay Elan a royalty on (i) any
[***] in connection with a Secondary Royalty Product, including [***] thereof; and (ii) the [***] of any Secondary
Royalty Product. Such royalty will equal [***] provided, however, that Elan will not be entitled to any royalties in the event a Secondary Royalty Product (x) utilizes
Know-How Controlled by [***]; (y) does not utilize any Know-How Controlled by [***] and (z) is administered to
humans [***] No royalties will be due on [***] with respect to a Secondary Royalty Product. 

        6.2  Payments
pursuant to Clauses 6.1.1 above, if any, shall be made semi annually in arrears within [***] days after the expiry of the applicable
period. The method of payment shall be by wire transfer to an account specified by Elan and shall be nonrefundable to Orasense. Each payment made 

9

 

to Elan shall be accompanied by a true accounting of all Royalty Products sold by Orasense, its Affiliates and its permitted sublicensees, if any, during such quarter. Such accounting shall show, on
a country-by-country and Royalty Product-by-Royalty Product basis, Net Sales, royalties and/or milestones received by Orasense (and the calculation
thereof) and each calculation of royalties with respect thereto, including the calculation of all adjustments and currency conversions. 

        6.3  Orasense
shall maintain and keep clear, detailed, complete, accurate and separate records for a period of [***] years following the completion of
such records so: (i) as to enable any royalties which shall have accrued hereunder to be determined; and (ii) that any deductions made in arriving at the Net Sales can be determined. 

        6.4  All
payments due hereunder shall be made in United States Dollars. Payments due on Net Sales of any Royalty Product, royalties or milestones received by Orasense with
respect to any Royalty Product for each calendar quarter made in a currency other than United States Dollars shall first be calculated in the foreign currency and then converted to United States
Dollars on the basis of the average exchange rate in effect for such quarter for the purchase of United States Dollars with such foreign currency quoted in the Wall Street Journal (or comparable
publication if not quoted in the Wall Street Journal) with respect to the currency of the country of origin of such payment, determined by averaging the rates so quoted on each business day of such
quarter. 

        6.5  If
Orasense claims in good faith that one or more of its devices, products, parts or components thereof, compounds and/or drug products is not a Royalty Product, then
Orasense shall within sixty (60) days of the date of receipt of any milestone payment or first commercial launch of any such devices, products, parts, or components thereof, or compounds notify
Elan in writing and establish same to Elan's reasonable satisfaction. 

        6.6  If,
at any time, legal restrictions in the Territory prevent the prompt payment when due of royalties or any portion thereof, the Parties shall meet to discuss suitable
and reasonable alternative methods of reimbursing Elan the amount of such royalties. In the event that Orasense is prevented from making any payment under this Agreement by virtue of the statutes,
laws, codes or government regulations of the country from which the payment is to be made, then such payments may be paid by depositing them in the currency in which they accrue to Elan's account in a
bank acceptable to Elan in the country the currency of which is involved or as otherwise agreed by the Parties. 

        6.7  Elan
and Orasense agree to co-operate in all respects necessary to take advantage of any double taxation agreements or similar agreements as may, from time
to time, be available. 

        6.8  Any
taxes payable by Elan on any payment made to Elan pursuant to this Agreement shall be for the account of Elan. If so required by applicable law, any payment made
pursuant to this Agreement shall be made by Orasense after deduction of the appropriate withholding tax, in which event the Parties shall co-operate to obtain the appropriate tax clearance
as soon as is practicable. On receipt of such clearance, Orasense shall forthwith procure that the amount so withheld is paid to Elan. 

        6.9  Orasense
shall, not more than [***] in each calendar year, permit Elan or its duly authorized representatives upon reasonable notice and at any
reasonable time during normal business hours to have access to inspect and audit the accounts and records of Orasense and any other book, record, voucher, receipt or invoice relating to the
calculation of the Royalty Payments submitted to Elan. Any such inspection of Orasense's records shall be at the expense of Elan, except that if any such inspection reveals a deficiency in the amount
of the royalty actually paid to Elan hereunder in any calendar quarter of [***] or more of the amount of any royalty actually due to Elan hereunder, then the expense of such
inspection shall be borne solely by Orasense. Any amount of deficiency shall be paid promptly to Elan by Orasense. If such inspection reveals a surplus in the amount of royalties actually paid to Elan
by Orasense, Elan shall reimburse Orasense the surplus within fifteen (15) days after determination. 

10

   
        6.10 In the event of any unresolved dispute regarding any alleged deficiency or overpayment of royalty payments hereunder, the matter will be subject to resolution in
accordance with Clause 24.9 of the Development Agreement, which is incorporated by reference and shall for such purposes survive termination of the Development Agreement. 

	7.
	CONFIDENTIAL INFORMATION

        7.1.  The
Parties acknowledge that it may be necessary, from time to time, to disclose to each other confidential and proprietary information, including without limitation,
Patents, inventions, works of authorship, trade secrets, specifications, designs, data, Know-How and other information relating to the Field, the Products, Elan Intellectual Property, Isis
Intellectual Property and Orasense Intellectual Property, as the case may be, processes, services and business of the disclosing Party. The foregoing shall be referred to collectively as "Confidential
Information". Any Confidential Information revealed by a Party to another Party shall be used by the receiving Party exclusively for the purposes of fulfilling the receiving Party's obligations under
this Agreement and the Development Agreement and for no other purpose. 

        7.2.  Each
Party agrees to disclose Confidential Information of another Party only to those employees, representatives and agents requiring knowledge thereof in connection
with their duties directly related to the fulfilling of the Party's obligations under this Agreement. Each Party further agrees to inform all such employees, representatives and agents of the terms
and provisions of this Agreement and their duties hereunder and to obtain their consent hereto as a condition of receiving Confidential Information. Each Party agrees that it will exercise the same
degree of care, but in no event less than a reasonable degree, and protection to preserve the proprietary and confidential nature of the Confidential Information disclosed by a Party, as the receiving
Party would exercise to preserve its own proprietary and confidential information. Each Party agrees that it will, upon request of a Party, return all documents and any copies thereof containing
Confidential Information belonging to or disclosed by, such Party. 

        7.3.  Notwithstanding
the above, each Party may use or disclose Confidential Information disclosed to it by another Party to the extent such use or disclosure is reasonably
necessary in filing or prosecuting patent applications, prosecuting or defending litigation, complying with patent applications, complying with applicable governmental regulations or otherwise
submitting information to tax or other governmental authorities, conducting clinical trials, or making a permitted sub-license or otherwise exercising its rights hereunder, provided that
if a Party is required to make any such disclosure of the other Party's Confidential Information, other than pursuant to a confidentiality agreement, such Party
shall inform the recipient of the terms and provisions of this Agreement and their duties hereunder and to obtain their consent hereto as a condition of receiving Confidential Information. 

        7.4.  Any
breach of this Clause 7 by any of the Persons informed by one of the Parties is considered a breach by the Party itself. 

        7.5.  Confidential
Information shall not be deemed to include: 

        7.5.1.  information
that is generally available to the public; 

        7.5.2.  information
which is made public by the disclosing Party; 

        7.5.3.  information
which is independently developed by a Party as evidenced by such Party's written records, without the aid, application or use of the
disclosing Party's Confidential Information; 

        7.5.4.  information
that is published or otherwise becomes part of the public domain without any disclosure by a Party, or on the part of a Party's directors,
officers, agents, representatives or employees; 

11

 

        7.5.5.  information
that becomes available to a Party on a non-confidential basis, whether directly or indirectly, from a source other than a Party,
which source did not acquire this information on a confidential basis; 

        7.5.6.  information
which the receiving Party is required to disclose pursuant to: 

        7.5.6.1.  a
valid order of a court or other governmental body or any political subdivision thereof or otherwise required by law; or 

        7.5.6.2.  any
other requirement of law; 

        provided
that if the receiving Party becomes legally required to disclose any Confidential Information, the receiving Party shall give the disclosing Party prompt notice of such fact so
that the disclosing Party may obtain a protective order or other appropriate remedy concerning any such disclosure. The receiving Party shall fully cooperate with the disclosing Party in connection
with the disclosing Party's efforts to obtain any such order or other remedy. If any such order or other remedy does not fully preclude disclosure, the receiving Party shall make such disclosure only
to the extent that such disclosure is legally required; 

        7.5.7.  information
which was already in the possession of the receiving Party at the time of receiving such information, as evidenced by its written records,
provided such information was not previously provided to the receiving Party from a source which was under an obligation to keep such information confidential; or 

        7.5.8.  information
that is the subject of a written permission to disclose, without restriction or limitation, by the disclosing Party. 

        7.6.  The
provisions relating to confidentiality in this Clause 7 shall remain in effect during the term of this Agreement, and for a period of
[***] years following the expiration or earlier termination of this Agreement but shall not apply to any information which a Party is required to file or otherwise disclose in
accordance with requirements which are legally binding on it. 

        7.7.  The
Parties agree that the obligations of this Clause 7 are necessary and reasonable in order to protect the Parties' respective businesses, and each Party
expressly agrees that monetary damages would be inadequate to compensate a Party for any breach by the other Party of its covenants and agreements set forth herein. Accordingly, the Parties agree and
acknowledge that any such violation or threatened violation will cause irreparable injury to a Party and that, in addition to any other remedies that may be available, in law and equity or otherwise,
any Party shall be entitled to obtain injunctive relief against the threatened breach of the provisions of this Clause 7, or a continuation of any such breach by the other Party, specific
performance and other equitable relief to redress such breach together with its damages and reasonable counsel fees and expenses to enforce its rights hereunder, without the necessity of proving
actual or express damages. 

        7.8.  Each
of the Parties shall be entitled to provide a copy of this Agreement (and any subsequent amendments hereto) and the Development Agreement to a potential third
party purchaser in connection with the sale of such Party's business or assets, including without limitation, in the case of Elan, the sale of the Elan Intellectual Property; provided that the
relevant third party purchaser or assignee has entered into a confidentiality agreement on terms no less protective than the terms of this Clause 7. 

	8.
	WARRANTIES AND INDEMNITIES

        8.1  Elan
represents and warrants to Orasense as of the Original Effective Date that: 

        8.1.1  Elan
is a corporation duly organized under the laws of its jurisdiction of organization and has all the requisite corporate power and authority to own
and lease its respective properties, 

12

 

to carry on its respective business as presently conducted and as proposed to be conducted and to carry out the transactions contemplated hereby; 

        8.1.2  Elan
has full corporate power and authority to enter into this Agreement and to perform its obligations hereunder, which have been duly authorized by all
requisite corporate action of Elan. This Agreement is the valid and binding obligation of Elan, enforceable against it in accordance with its terms, except as limited by applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting the enforcement of creditors' rights generally, and by general equity principles and limitations on the
availability of equitable relief, including specific performance; 

        8.1.3  the
execution, delivery and performance by Elan of this Agreement will not: (i) violate any provision of applicable law, statute, rule or
regulation known by and applicable to Elan or any ruling, writ, injunction, order, judgment or decree of any court, arbitrator, administrative agency or other governmental body applicable to Elan or
any of its properties or assets; or (ii) conflict with or result in any breach of any of the terms, conditions or provisions of, or constitute (with notice or lapse of time or both) a default
(or give rise to any right of termination, cancellation or acceleration) under the charter or organizational documents of Elan to which Elan is a party, except where such violation, conflict or breach
would not, individually or in the aggregate, have an adverse material effect on the business, assets, liabilities (contingent or otherwise), operations, condition (financial or otherwise), or
prospects of Elan; 

        8.1.4  to
Elan's best knowledge, except as set forth on Schedule 3 hereto, (i) Elan has the right to grant the Elan License, (ii) there are
no agreements between Elan and any third parties that conflict with the Elan License which would have a material adverse effect on the ability of Orasense to conduct its business as presently proposed
to be conducted, (iii) Elan is the owner or licensee of all rights, title and interest in the Elan Intellectual Property; and (v) [***] 

        8.2  Orasense
represents and warrants to Elan as of the Original Effective Date that: 

        8.2.1  Orasense
is duly and validly existing in good standing in the jurisdiction of its incorporation and each other jurisdiction in which the conduct of its
business requires such qualification (except where such failure to so qualify shall not have a material adverse affect on the business and assets of
Orasense), and Orasense is in compliance with all applicable laws, rules, regulations or orders relating to its business and assets; 

        8.2.2  Orasense
has full corporate authority to execute and deliver this Agreement and to consummate the transactions contemplated hereby; this Agreement has
been duly executed and delivered and constitutes the legal and valid obligations of Orasense and is enforceable against Orasense in accordance with its terms; and the execution, delivery and
performance of this Agreement and the transactions contemplated hereby will not violate or result in a default under or creation of lien or encumbrance under Orasense's certificate of incorporation,
by-laws or other organizational documents, any material agreement or instrument binding upon or affecting Orasense, or its properties or assets or any applicable laws, rules, regulations
or orders affecting Orasense or its properties or assets; 

        8.2.3  Orasense
is not in default of its charter or by-laws, any applicable laws or regulations or any material contract or agreement binding upon
or affecting it or its properties or assets and the execution, delivery and performance of this Agreement and the transactions contemplated hereby will not result in any such violation; 

        8.2.4  Orasense
represents and warrants to Elan that the execution of this Agreement by Orasense and the full performance and enjoyment of the rights of
Orasense under this Agreement will not breach the terms and conditions of any license, contract, understanding or agreement, whether express, implied, written or oral between Orasense and any third
party; 

13

 

        8.2.5  Orasense
represents and warrants to and covenants with Elan that it has the sole, exclusive and unencumbered right to grant the licenses and rights
herein granted to Elan and that it has not granted and will not grant any option, license, right or interest in or to the Elan Intellectual Property, the Orasense Collaboration Intellectual Property,
or other property to any third party which would conflict with the rights granted by this Agreement; 

        8.2.6  the
Products shall be developed, manufactured, transported, stored, handled, Packaged, marketed, promoted, distributed, offered for sale, sold and
otherwise Commercialized in accordance with all regulations and requirements of the FDA and foreign governmental authorities having jurisdiction in such country or countries in the Territory
including, without limitation, cGCP, cGLP, cGMP regulations. 

        8.2.7  the
Products shall not be adulterated or misbranded as defined by the Federal Food, Drug and Cosmetic Act (or applicable foreign law) and shall not be a
product which would violate any section of such Act if introduced in interstate commerce; 

        8.2.8  it
is fully cognizant of all applicable statutes, ordinances and regulations of the United States of America and countries in the Territory with respect
to the manufacture of the Products including, but not limited to, the U.S. Federal Food, Drug and Cosmetic Act and regulations thereunder and similar statutes in countries outside of the United
States. Orasense shall manufacture or procure the manufacture of the Products in conformity with the Marketing Authorizations and in a manner which fully complies with all United States of America and
foreign statutes, ordinances, regulations and practices. 

        8.3  In
addition to any other indemnifications provided for herein, Elan shall indemnify and hold harmless Orasense and its Affiliates and their respective employees, agents,
partners, officers and directors from and against any claims, losses, liabilities or damages (including reasonable attorney's fees and expenses) incurred or sustained by Orasense arising out of or in
connection with any (a) breach of any representation, covenant, warranty or obligation by Elan hereunder, or (b) any act or omission on the part of Elan or any of its agents or employees
in the performance of this Agreement. 

        8.4  In
addition to any other indemnifications provided for herein, Orasense and Isis and any of their respective sublicensees shall indemnify and hold harmless Elan and its
Affiliates, and each of Elan's and its Affiliates' respective employees, agents, partners, officers and directors (each an "Indemnified Party") from and against any claims, losses, liabilities or
damages (including reasonable attorney's fees and expenses) incurred or sustained by an Indemnified Party arising out of or in connection with any (a) breach of any representation, covenant,
warranty or obligation by Orasense or its sublicensees hereunder, or (b) any act or omission on the part of Orasense, Isis or any of their respective sublicensees in connection with the
research, development, manufacture and/or Commercialization of any Product hereunder, including without limitation, with respect to the conduct of any clinical trials and death or injury to any
person. 

        8.5  Orasense
and Isis shall each obtain prior to conducting any clinical trial in respect of the Product appropriate comprehensive general liability insurance and/or other
insurance coverage (the "Policies"), and shall each maintain such Policies during such clinical trials and for a period of five years thereafter. Orasense and Isis shall furnish Elan with copies of
all Policies that it holds in respect of such clinical trials. 

        8.6  Any
Party seeking an indemnity hereunder shall: 

        8.6.1  fully
and promptly notify the other Party of any claim or proceeding, or threatened claim or proceeding; 

        8.6.2  permit
the indemnifying Party to take full care and control of such claim or proceeding; 

        8.6.3  cooperate
in the investigation and defense of such claim or proceeding; 

14

 

        8.6.4  not
compromise or otherwise settle any such claim or proceeding without the prior written consent of the other Party, which consent shall not be
unreasonably withheld, conditioned or delayed; and 

        8.6.5  take
all reasonable steps to mitigate any loss or liability in respect of any such claim or proceeding. 

        8.7  NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, NEITHER ELAN NOR ORASENSE SHALL BE LIABLE TO THE OTHER PARTY, BY REASON OF ANY
REPRESENTATION OR WARRANTY, CONDITION OR OTHER TERM OR ANY DUTY OF COMMON LAW, OR UNDER THE EXPRESS TERMS OF THIS AGREEMENT, FOR ANY CONSEQUENTIAL, SPECIAL OR INCIDENTAL LOSS OR DAMAGE (WHETHER FOR
LOSS OF PROFIT OR OTHERWISE) AND WHETHER OCCASIONED BY THE APPLICABLE PARTY'S NEGLIGENCE OR OF ITS EMPLOYEES OR AGENTS OR OTHERWISE.

        8.8  EXCEPT AS SET FORTH IN THIS CLAUSE 8, ELAN IS GRANTING THE ELAN LICENSE HEREUNDER ON AN "AS IS" BASIS WITHOUT RECOURSE, REPRESENTATION OR
WARRANTY WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR INFRINGEMENT OF THIRD PARTY RIGHTS, AND ALL SUCH WARRANTIES ARE EXPRESSLY
DISCLAIMED.

	9
	INTELLECTUAL PROPERTY OWNERSHIP RIGHTS

        9.1  Title
and all other ownership rights, including patent rights, relating to the Elan Intellectual Property shall belong to Elan. 

        9.2  Each
Party shall own the legal and equitable title to any invention invented by such Party that is not Orasense Intellectual Property. 

        9.3  Orasense
shall permanently mark or otherwise use reasonable efforts to cause any third party to permanently mark all Products and/or the Packaging therefor with such
license or patent notices to comply with the applicable laws of each country of sale of the Territory or otherwise to generally communicate the existence of any of Patents under the Elan Intellectual
Property for the countries of
the Territory and in such manner as Elan may reasonably request in writing following receipt of written notice by Orasense of its intent to Commercialize a Product. 

        9.4  Elan
shall have the sole and exclusive right to (i) secure any Patents under the Elan Intellectual Property; (ii) defend all Patents under the Elan
Intellectual Property against third party oppositions; and (iii) maintain in force any material issued letters patent within the Patents under the Elan Intellectual Property. Elan shall have
the sole right, in its discretion, to control such filing, prosecution, defense and maintenance of any Patents under the Elan Intellectual Property. 

        9.5  In
the event that Elan informs Orasense and Isis that it does not intend to file patent applications on patentable inventions and discoveries within the Elan
Intellectual Property that relate to the Field in one or more countries in the Territory or fails to file such an application within a reasonable period of time, Orasense shall have the option at its
expense to file and prosecute such patent application(s) in the joint names of Orasense and Elan unless Elan believes that the prosecution and maintenance of any such Patent may be harmful to Elan's
or its Affiliates' general patent strategy, business objectives, or is illegal or without adequate foundation. Subject to the preceding sentence, Elan shall reasonably cooperate with Orasense at
Orasense's sole cost and expense and shall execute such documents as are reasonably necessary to continue the prosecution and maintenance of such patent application. 

        9.6  Orasense,
Isis and Elan shall promptly inform each other in writing of any alleged infringement of any patents within the Patents within the Elan Intellectual Property
and the Orasense Intellectual Property or any alleged misappropriation of trade secrets within the Elan Intellectual 

15

 

Property or the Orasense Intellectual Property by a third party of which it becomes aware and provide the others with any available evidence of such infringement or misappropriation insofar as such
infringements or misappropriation relate solely to the Field. 

        9.7  Orasense
shall have the right to prosecute at its own expense and for its own benefit any infringements of the Patents within the Elan Intellectual Property or
misappropriation of the Elan Intellectual Property, insofar as such infringements or misappropriation relate solely to the Field. In the event that Orasense takes such action, Orasense shall do so at
its own cost and expense. At Orasense's request, Elan shall cooperate with such action. Any recovery in relation to such infringement proceeding shall belong to Orasense. Should Orasense decide not to
pursue such infringers, within a reasonable period but in any event within [***] days after receiving written notice of such alleged infringement or misappropriation Elan may
in its discretion initiate such proceedings in its own name, at its expense and for its own benefit, and at Elan's request, Orasense shall cooperate with such action. Alternatively, Orasense and Elan
may agree to institute such proceedings in their joint names and shall reach agreement as to the proportion in which they shall share the proceeds of any such proceedings, and the expense of any costs
not recovered, or the costs or damages payable to the third party. If the infringement of the Patents within the Elan Intellectual Property affects both the Field as well as other products being
developed or commercialized by Elan or its commercial partners outside the Field, Orasense and Elan shall endeavor to agree as to the manner in which the proceedings should be instituted and as to the
proportion in which they shall share the proceeds of any such proceedings, and the expense of any costs not recovered, or the costs or damages payable to the third party. 

	10
	RIGHTS EXPLOITATION OUTSIDE THE FIELD

        10.1    Licenses to Orasense Collaboration Intellectual Property.    Subject to the Non-Competition
provisions in Clause 11 hereof, Orasense hereby grants to Elan a royalty free and fully sublicensable [***] license with Isis [***] in the
Territory, to practice Orasense Collaboration Intellectual Property, such license to expire, on a country-by-country and Product-by-Product basis, upon
the date of (i) the last to expire Patent under the Orasense Collaboration Intellectual Property; or (ii) [***] years from the first commercial sale of a product
incorporating the Orasense Collaboration Intellectual Property, whichever is later. 

        10.2 [***].

	11
	NON-COMPETITION

        During
[***], Elan shall not develop or Commercialize, or assist in the development or Commercialization of an [***], except
(a) for or on behalf of Orasense, or (b) with the prior written, unanimous consent of the Management Committee. During the Research Term and provided that Orasense is maintaining an
active program for the development and Commercialization of the Development Candidate in the Field, Elan shall not develop or Commercialize or assist in the development for Commercialization of
[***] Nothing contained herein shall be construed as (i) limiting the activities of an existing third party licensee of Elan from developing Oligonucleotide Drugs
utilizing Elan Intellectual Property to the extent such rights have been previously granted by Elan, provided Elan does not provide any active support to any such activities in excess of its existing
contractual obligations or (ii) prohibiting Elan from licensing Elan Intellectual Property to an Independent Third Party or limiting the activities of any such future Independent Third Party
licensee of Elan from developing [***] utilizing Elan Intellectual Property [***]. 

	12
	TERM AND TERMINATION OF AGREEMENT

        12.1 The
term of this Agreement and the term of the Licenses granted hereunder with respect to a Product utilizing or based on the Licensed Technologies shall commence as of
the Effective Date and continue, on a Product-by-Product basis and country by country basis, for the life of the Patent rights upon which such Product is based on or utilizes
in such country (the "Term"); provided, however, that 

16

 

all royalty and fee obligations contained herein shall survive for the greater of (i) the Term or (ii) [***] years from the first commercial sale of such
Product. 

        12.2 Nothing
contained herein shall obligate or restrict any party from utilizing public, non-proprietary information which is not subject to the protection of
applicable patent laws. 

        12.3 If
any Party breaches any material provision of this Agreement and if such breach is (i) not capable of being cured or (ii) is capable of being cured but
is not [***] after the non-breaching Party gives written notice of the breach to the breaching Party, the non-breaching Party may terminate this
Agreement immediately by giving notice of the termination to the breaching Party, effective on the date of the notice, provided, however, that
(x) so long as the breaching Party takes substantial steps to cure the breach promptly after receiving notice of the breach from the non-breaching party and thereafter diligently
prosecutes the cure to completion as soon as is practicable, the non-breaching Party may not terminate this Agreement so long as the breaching party is acting in good faith to rectify such
breach, or (y) the default involves a good faith dispute regarding the amount of any required payment, provided any undisputed amount is timely paid, such default shall be stayed and the
remainder may be withheld so long as the withholding Party is proceeding in good faith to resolve the dispute. 

        12.4 In
the event that the Isis License Agreement shall be terminated, at the sole option of Elan and upon written notice to Isis and Orasense, the Elan License shall be
immediately terminated. 

        12.5 Upon
the occurrence of an Event of Bankruptcy with respect to Orasense, Isis or Elan, the other Party may, upon written notice to Isis and the Party with respect to
which such Event of Bankruptcy has occurred, immediately terminate the Elan License. As used in this Clause 12.5, the term "Event of Bankruptcy" relating to either Orasense or Elan shall mean: 

        12.5.1  the
appointment of a liquidator, receiver, administrator, examiner, trustee or similar officer of either Party of it or over all or a substantial part
of its assets under the law of any applicable jurisdiction, including without limit, Bermuda, the United States of America or Ireland; or 

        12.5.2  an
application or petition for bankruptcy, corporate re-organization, composition, administration, examination, arrangement or any other
procedure similar to any of the foregoing under the law of any applicable jurisdiction, including without limit, Bermuda, the United States of America or Ireland (other than as part of a bona fide
restructuring or reorganization), is filed, and is not discharged within [***] days, or if either Party applies for or consents to the appointment of a receiver, administrator,
examiner or similar officer of it or of all or a material part of its assets, rights or revenues or the assets and/or the business of either Party are for any reason seized, confiscated or condemned. 

        12.6 Upon
exercise of those rights of termination as specified in Clause 12.1 to Clause 12.5 inclusive or elsewhere within this Agreement, this Agreement
shall, subject to the other provisions of this Agreement, automatically terminate forthwith and be of no further legal force or effect. 

        12.7 Upon
expiration or termination of the Agreement: 

        12.7.1  any
sums that were due from Orasense to Elan under Clause 6, including without limitation on Net Sales, in the Territory or in such particular
country or countries in the Territory (as the case may be) prior to the expiration or termination of this Agreement as set forth herein shall be paid in full within [***] days
after the expiration or termination of this Agreement for the Territory or for such particular country or countries in the Territory (as the case may be); 

        12.7.2  any
provisions clearly meant to survive termination or expiration of this Agreement, including without limitation Clause 7, shall remain in full
force and effect; 

17

 

        12.7.3  all
representations, warranties and indemnities shall insofar as are appropriate remain in full force and effect; 

        12.7.4  the
rights of inspection and audit set out in Clause 12.6 shall continue in force for a period of [***] 

        12.7.5  termination
of this Agreement for any reason shall not release any Party hereto from any liability which, at the time of such termination, has already
accrued to the other Party or which is attributable to a period prior to such termination nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity
with respect to any breach of this Agreement; 

        12.7.6  the
Elan Intellectual Property and all rights, licenses and sublicenses granted by Elan in and pursuant to this Agreement shall cease for the Territory
or for such particular country or countries in the Territory (as the case may be) and shall immediately revert to Elan. Following such expiration or termination, Orasense may not thereafter use in the
Territory or in such particular country or countries in the Territory (as the case may be) (a) any valid and unexpired Patents in the Elan Intellectual Property and/or (b) any Elan
Intellectual Property that remains confidential or otherwise proprietary to Elan. All rights to Orasense Intellectual Property will be transferred to and owned by Orasense. Rights of permitted
Independent Third Party sublicensees in and to the Elan Intellectual Property shall survive the termination of the license and sublicense agreements granting said intellectual property rights to
Orasense; and Orasense, Elan and Isis shall in good faith agree upon the form most advantageous to Isis and Elan in which the rights of the sublicensor under any such sublicenses are to be held (which
form may include continuation of Orasense solely as the holder of such licenses or assignment of such rights to a third party or parties, including an assignment to both Elan and Isis). Any sublicense
agreement between Orasense and such permitted sublicensee shall permit an assignment of rights by Orasense to Elan and shall contain additional reasonable confidentiality protections which an assignee
shall reasonably require. Upon any such assignment, Isis and Elan shall enter into good faith
negotiations with respect to additional reasonable confidentiality protections which either party shall reasonably require. 

	13
	FORCE MAJEURE

        13.1 Neither
Party to this Agreement shall be liable for delay in the performance of any of its obligations hereunder if such delay results from causes beyond its reasonable
control, including, without limitation, acts of God, fires, strikes, acts of war, or intervention of a government authority, non availability of raw materials, but any such delay or failure shall be
remedied by such Party as soon as practicable; provided, however, that neither party hereunder shall be excused for delay in the performance of any of its payment obligations hereunder. 

	14
	SETTLEMENT OF DISPUTES; GOVERNING LAW

        14.1 Any
dispute between the Parties arising out of or relating to this Agreement will be subject to resolution in accordance with Clause 24.9 of the Development
Agreement, which is incorporated by reference and shall for such purposes survive termination of the Development Agreement. 

        14.2 This
Agreement is construed under and ruled by the laws of the State of New York, without regard to the conflict of law principles. 

	15
	ASSIGNMENT

        This
Agreement may not be assigned by either Party without the prior written consent of the other, which consent shall not be unreasonably withheld, conditioned or delayed, save that
(i) either Party may assign this Agreement to its Affiliate without such consent, provided that such assignment does not have any adverse tax consequences on the other Party, and (ii) 
Elan may assign its rights and 

18

 

obligations hereunder in connection with a sale of its business or sale of any of the Elan Intellectual Property licensed hereunder, whether by merger, sale of stock, sale of assets or otherwise.
Elan and Orasense will discuss any assignment by either Party to an Affiliate prior to its implementation in order to avoid or reduce any additional tax liability to the other Party resulting solely
from different tax law provisions applying after such assignment to an Affiliate. For the purpose hereof, an additional tax liability shall be deemed to have occurred if either Party would be subject
to a higher net tax on payments made hereunder after taking into account any applicable tax treaty and available tax credits than such Party was subject to before the proposed assignment.
Notwithstanding any assignment hereof to an Affiliate, each Party will remain fully liable hereunder. 

	16
	NOTICES

        16.1 Any
notice to be given under this Agreement shall be sent in writing in English by registered airmail or telefaxed to the following addresses: 

	If to Orasense at:	 	Orasense Ltd.

c/o Isis Pharmaceuticals, Inc.

2292 Faraday Avenue

Carlsbad, California 92008
	 	 	Attention:	 	Ms. Lynne Parshall
	 	 	Telephone:	 	(760) 603-2460
	 	 	Telefax:	 	(760) 931-9639
	

If to Isis to:	
 	

Isis Pharmaceuticals, Inc.

2292 Faraday Avenue

Carlsbad, California 92008
	 	 	Attention:	 	Ms Lynne Parshall
	 	 	Telephone:	 	(760) 603-2460
	 	 	Telefax:	 	(760) 931-9639
	

with a copy to:	
 	

Isis Pharmaceuticals, Inc.

2292 Faraday Avenue

Carlsbad, CA 92008
	 	 	Attention:	 	Grantland E. Bryce
	 	 	Telephone:	 	760-603-2707
	 	 	Fax:	 	760-268-4922
	

If to Elan at:	
 	

Elan Corporation, plc

C/o Elan International Services, Ltd.

102 St. James Court

Flatts,

Smiths FL04

Bermuda
	 	 	Attention:	 	Secretary
	 	 	Telephone:	 	441 292 9169
	 	 	Fax:	 	441 292 2224

or
to such other address(es) and telefax numbers as may from time to time be notified by either Party to the other hereunder. 

        16.2 All
notices and other communications given to any Party hereto in accordance with the provisions of this Agreement will be deemed to have been given on the date of
receipt if delivered by hand or overnight courier service or sent by confirmed telecopy to such Party as provided in this Clause 

19

 

or in accordance with the latest unrevoked direction from such Party given in accordance with this Clause 16. 

	17
	MISCELLANEOUS CLAUSES

        17.1 No
waiver of any right under this Agreement shall be deemed effective unless contained in a written document signed by the Party charged with such waiver, and no waiver
of any breach or failure to perform shall be deemed to be a waiver of any other breach or failure to perform or of any other right arising under this Agreement. 

        17.2 If
any provision in this Agreement is agreed by the Parties to be, or is deemed to be, or becomes invalid, illegal, void or unenforceable under any law that is
applicable hereto, 

        17.2.1  such
provision will be deemed amended to conform to applicable laws so as to be valid and enforceable or, if it cannot be so amended without materially
altering the intention of the Parties, it
will be deleted, with effect from the date of such agreement or such earlier date as the Parties may agree; and 

        17.2.2  the
validity, legality and enforceability of the remaining provisions of this Agreement shall not be impaired or affected in any way. 

        17.3 The
Parties shall use their respective reasonable endeavors to ensure that the Parties and any necessary third party shall execute and perform all such further deeds,
documents, assurances, acts and things as any of the Parties hereto may reasonably require by notice in writing to the other Party or such third party to carry the provisions of this Agreement. 

        17.4 This
Agreement shall be binding upon and inure to the benefit of the Parties hereto, their successors and permitted assigns and sublicensees. 

        17.5 No
provision of this Agreement shall be construed so as to negate, modify or affect in any way the provisions of any other agreement between the Parties unless
specifically referred to, and solely to the extent provided, in any such other agreement. In the event of a conflict between the provisions of this Agreement and the provisions of the Development
Agreement, the terms of this Agreement shall prevail. 

        17.6 No
amendment, modification or addition hereto shall be effective or binding on either Party unless set forth in writing and executed by a duly authorized representative
of each Party. Amendments hereto shall be subject to the prior approval of Elan, which approval shall not be unreasonably withheld or delayed. 

        17.7 This
Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together
shall constitute this Agreement. 

        17.8 Each
of the Parties undertakes to do all things reasonably within its power which are necessary or desirable to give effect to the spirit and intent of this Agreement. 

        17.9 Each
of the Parties hereby acknowledges that in entering into this Agreement it has not relied on any representation or warranty save as expressly set out herein or in
any document referred to herein. 

        17.10
Nothing contained in this Agreement is intended or is to be construed to constitute Elan, Isis and Orasense as partners, or Isis as an employee of Orasense and Elan,
or Orasense and Elan as an
employee of Isis. Neither Party hereto shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other
Party to any contract, agreement or undertaking with any third party. 

20

   
        IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the date first set forth above. 

	 	ELAN CORPORATION, PLC	 	 	ISIS PHARMACEUTICAL, INC.
	

By:	

/s/  KEVIN INSLEY      
	
 	

By:	

/s/  B. LYNNE PARSHALL      

	

 	

Kevin Insley
 Name	
 	

 	

B. Lynne Parshall
 Name
	 	    
	 	 	    

	 	Title Authorized Signatory	 	 	Title Executive VP, CFO, Director
	 	    
	 	 	    

	 	Date	 	 	Date
	

 	
ORASENSE, LTD.
 	
 	

 	

 
	

By:	

/s/  E.C. (NED) JACKSON      
	
 	

 	

 
	

 	

E.C. (Ned) Jackson
 Name	
 	

 	

 
	 	    
 Title	 	 	 
	 	    
 Date	 	 	 

21

   SCHEDULE 1  

 ELAN PATENTS  

        [***] 

22

   SCHEDULE 2  

 ORASENSE COLLABORATION INTELLECTUAL PROPERTY  

        [***] 

23

QuickLinks

AMENDED AND RESTATED LICENSE AGREEMENT BY AND BETWEEN ORASENSE LTD A Bermuda Limited Company ISIS PHARMACEUTICALS, INC A Delaware Corporation AND ELAN CORPORATION, PLC A Public Irish Company October 24,
2002QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.3  

        CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.R.F §§ 200.80(B)4 AND 240.24B-2 

JDOA

Execution Copy (V8)

24 October 2002  

 
 

AMENDED AND RESTATED    
    
    SUBSCRIPTION, JOINT DEVELOPMENT AND OPERATING AGREEMENT    
    
    ELAN CORPORATION, PLC    
    
    ELAN INTERNATIONAL SERVICES, LTD.    
    
    ISIS
PHARMACEUTICALS, INC.    
    
    AND    
    
    ORASENSE LTD.    
    
    October 24, 2002    

        THIS AMENDED AND RESTATED SUBSCRIPTION, JOINT DEVELOPMENT AND OPERATING AGREEMENT is made this 24th day of
October 2002, 

among:  

        (1)  ELAN CORPORATION, PLC, a public limited company incorporated under the laws of Ireland, and having its registered office
at Lincoln House, Lincoln Place, Dublin 2, Ireland ("Elan"); 

        (2)  ELAN INTERNATIONAL SERVICES, LTD., a private limited company incorporated under the laws of Bermuda, and having
its registered office at Clarendon House, 2 Church St., Hamilton, Bermuda ("EIS"); 

        (3)  ISIS PHARMACEUTICALS, INC., a corporation incorporated under the laws of Delaware and having its principal place
of business at 2292 Faraday Avenue, Carlsbad, CA 92008, United States of America ("Isis"); and 

        (4)  ORASENSE LTD., a private limited company incorporated under the laws of Bermuda, and having its registered office
at Clarendon House, 2 Church St., Hamilton, Bermuda ("Orasense"). 

RECITALS:  

        Capitalized terms shall have the meanings set forth below unless otherwise defined. 

        D.    As
of the date hereof, Elan (as defined below) has entered into the Elan License Agreement with Orasense and Isis, and Isis has entered into the Isis License Agreement
with Orasense and Elan, in connection with the license to Orasense of the Elan Intellectual Property and the Isis Intellectual Property, respectively. 

        E.    Elan
and Isis have agreed to co-operate in the management of Orasense for the research, development and Commercialization of the Product based on their
respective technologies. 

        F.    Elan,
EIS, Isis and Orasense are parties to that certain Subscription, Joint Development and Operating Agreement (the "Original Agreement") dated April 20, 1999
(the "Original Effective Date"). The parties have agreed to enter into this Agreement for the purpose of amending and restating the Original Agreement and recording the terms and conditions of the
joint venture and of regulating their relationship with each other and certain aspects of the affairs of and their dealings with Orasense. 

NOW IT IS HEREBY AGREED AS FOLLOWS:  

CLAUSE 1  

 DEFINITIONS  

        1.1  In
this Agreement, the following terms shall, where not inconsistent with the context, have the following meanings respectively. 

        "Affiliate" shall mean, with respect to Isis or Elan, any corporation or entity other than Orasense (and entities controlled by it)
controlling, controlled or under the common control of Isis or Elan, as the case may be, and, with respect to Orasense, any corporation or entity under control of Orasense, but excluding, in the case
of Elan, an Elan JV. A corporation or non-corporate entity shall be regarded as in control of another corporation if it owns or directly or indirectly controls at least fifty percent (50%)
of the voting stock of the other corporation or (a) in the absence of the ownership of at least fifty percent (50%) of the voting stock of a corporation or (b) in the case of a
non-corporate entity, the power to direct or cause the direction of the management and policies of such corporation or non-corporate entity, as applicable. 

        "Agreement" shall mean this amended and restated agreement (which expression shall be deemed to include the Recitals and the Schedules
hereto). 

 

        "Business" shall mean the business of Orasense as described in Clause 2 and as more particularly specified in the Research Plan and
such other business as the Directors may agree from time to time in writing should be carried on by Orasense. 

        "Commercialization" shall mean the manufacture, promotion, distribution, marketing and sale of the Products. 

        "Common Stock" shall mean the common stock, par value $1.00 per share of Orasense. 

        "Common Stock Equivalents" shall mean any options, warrants, rights or any other securities convertible, exercisable or exchangeable, in
whole or in part, for or into Common Stock. 

        "Control" shall mean the ability of Elan, Isis or Orasense, as the case may be, to grant a license or sublicense as contemplated herein
without having to obtain the prior consent of any third party or having to amend any agreement between Elan, Isis or Orasense, as the case may be, and a third party. 

        "Development Candidate" shall mean, ISIS 104838, [***] TNF-a, as
more specifically detailed in the License Agreements. 

        "Development Product" shall mean any product containing as an active ingredient the Development Candidate formulated using the Oral
Platform for humans. 

        "Directors" shall mean, at any time, the directors of Orasense. 

        "EIS Director" shall have the meaning set forth in Clause 7. 

        "Elan Intellectual Property" shall have the meaning set forth in the Elan License Agreement. 

        "Elan License" shall have the meaning set forth in the Elan License Agreement. 

        "Elan License Agreement" shall mean the amended and restated license agreement between Elan, Orasense and Isis, of even date herewith. 

        "Elan Minority Interest" will be deemed to have occurred if at any time after [***], Elan's ownership interest in
Orasense falls below [***] 

        "Encumbrance" shall mean any liens, charges, encumbrances, equities, claims, options, proxies, pledges, security interests, or other
similar rights of any nature. 

        "Exchange Act" shall mean the Securities Exchange Act of 1934, as amended. 

        "Failure to Fund" shall have the meaning set forth in Section 9.5. 

        "Field" shall mean the research, development and Commercialization of the Oral Platform for use with Oligonucleotide Drugs. 

        "Financial Year" means each year commencing on January 1 (or in the case of the first Financial Year, the date hereof) and expiring
on December 31 of each year. 

        "Fully Diluted Common Stock" shall mean all of the issued and outstanding Common Stock, assuming the conversion, exercise or exchange of
all outstanding Common Stock Equivalents. 

        "Independent Third Party" shall mean any person other than Orasense, Isis, Elan or any of their respective Affiliates. 

        "Isis Blocking Invention" shall mean [***] 

        "Isis Delivery Technology" shall have the meaning given to such term in the Isis License Agreement. 

        "Isis Directors" has the meaning set forth in Clause 7. 

2

 

        "Isis Intellectual Property" shall have the meaning set forth in the Isis License Agreement. 

        "Isis License" shall have the meaning set forth in the Isis License Agreement. 

        "Isis License Agreement" shall mean the amended and restated license agreement between Isis, Orasense and Elan, of even date herewith. 

        "Isis Oligonucleotide Drug" shall mean any Oligonucleotide Drug Controlled by Isis other than the Development Candidate. 

        "Know-How" shall mean any and all rights to any discovery, invention (whether or not patentable), know-how,
substances, data, techniques, processes, systems, formulations and designs which is not generally known to the public. 

        "License Agreements" shall mean the Elan License Agreement and the Isis License Agreement. 

        "Licensed Technologies" shall mean together, the Elan Intellectual Property and the Isis Intellectual Property. 

        "Oligonucleotide Drug" shall mean any single stranded [***] at physiological pH oligonucleotide including those
with [***] used as a human therapeutic and/or prophylactic compound containing between [***] nucleotides and/or nucleosides including oligonucleotide
analogs which may include [***]. For purposes of this agreement, Oligonucleotide Drug shall specifically exclude oligonucleotides used in
[***], oligonucleotides used [***] an oligonucleotide, oligonucleotides used as [***] or oligonucleotides used as
[***]. 

        "Oral" shall mean administration by way of the mouth for the purpose of topical or systemic delivery by way of the alimentary canal. 

        "Oral Platform" shall mean formulation and excipient systems and technologies [***] which use
[***] to develop dosage forms of drugs and deliver said dosage forms to the [***] to achieve a local or systemic therapeutic effect. 

        "Orasense Memorandum of Association and Bye-Laws" shall mean the Memorandum of Association and Bye-Laws of
Orasense. 

        "Orasense Blocking Invention" shall mean [***] 

        "Orasense Collaboration Intellectual Property" shall mean (a) Know-How Controlled by Orasense through the end of the
Research Term, (b) Patents Controlled by Orasense claiming inventions made on or before the end of the Research Term, and/or (c) inventions and Patents issued thereon developed by
Orasense, Isis and/or Elan on behalf of Orasense (or any third party under contract with Orasense, Isis and/or Elan) or otherwise under the Original Research Plan or the Research Plan.
Schedule 1 to this Agreement shall contain, by way of illustration but not limitation, examples of Orasense Collaboration Intellectual Property. At the end of the Research Term, the Parties
shall amend Schedule 1 as may be necessary. For the avoidance of doubt, Orasense Collaboration Intellectual Property does not include any Patents and/or Know-How Controlled by Elan
or Isis, as the case may be. 

        "Orasense Intellectual Property" shall mean Orasense Collaboration Intellectual Property and Orasense Post Collaboration Intellectual
Property. 

        "Orasense Post-Collaboration Intellectual Property" shall mean (a) Know-How Controlled by Orasense after
the end of the Research Term, (b) Patents Controlled by Orasense claiming inventions made after the end of the Research Term, and/or (c) inventions and Patents issued thereon made by
Isis on Orasense's behalf after a Failure to Fund. For the avoidance of doubt, Orasense Post-Collaboration Intellectual Property does not include any Patents and/or Know-How
Controlled by Elan or Isis, as the case may be. 

3

 

        "Original Research Plan" means the Research and Development Program under the Original Agreement. 

        "Participant" means Isis or Elan, as the case may be, and "Participants" means both of the Participants together. 

        "Party" means Elan, Isis, or Orasense, as the case may be, and "Parties" means all three together. 

        "Patents" shall mean any and all patents and patent applications. Patents shall also include all extensions, continuations, divisionals,
patents-of-additions, re-examinations, re-issues, supplementary protection certificates and foreign counterparts of such patents and patent applications
and any patents issuing thereon and extensions of any patents licensed hereunder. 

        "Person" means an individual, partnership, corporation, limited liability company, business trust, joint stock company, trust,
unincorporated association, joint venture, governmental entity or authority or other entity of whatever nature. 

        "Permitted Transferee" means any Affiliate or subsidiary of Elan, EIS or Isis, to whom this Agreement may be assigned, in whole or in
part, pursuant to the terms hereof or in the case of Elan/EIS, an off-balance sheet special purpose entity created by Elan or EIS. 

        "Product" shall mean any drug under development or developed by or on behalf of Orasense made or formulated using the Isis Delivery
Technology, the Elan Intellectual Property and/or the Orasense Intellectual Property for administration to humans. 

        "Registration Rights Agreements" means the Registration Rights Agreements dated April 20, 1999 relating to securities of Isis and
Orasense, respectively. 

        "Regulatory Application" shall mean a regulatory application or other application (including any supplements or amendments thereto)
required to be filed or filed with a Regulatory Authority in a country in connection with the Commercialization of a pharmaceutical product in such country. 

        "Regulatory Approval" means the final approval required to Commercialize a Product in each country of the Territory, and any other
approval which is required to launch a product in the normal course of business. 

        "Research Plan" shall mean the program of development, including a budget, attached hereto as Schedule 2 which is hereby agreed to
by Elan and Isis as of the Effective Date, with respect to the research, development, and commercialization of the Oral Platform and the Development Candidate. 

        "Research Term" shall mean the period commencing on [***] and continuing through [***],
and any extension thereto by the mutual agreement of Isis and Elan. 

        "Regulatory Authority" shall mean any regulatory authority outside the United States of America, the approval of which is necessary to
market a Product. 

        "Securities Act" means the Securities Act of 1933, as amended. 

        "Shares" means the shares of Common Stock of Orasense. 

        "Stockholder" means any of EIS, Isis, any Permitted Transferee or any other Person who subsequently becomes bound by this Agreement as a
holder of the Shares, and "Stockholders" means all of the Stockholders together. 

        "Term" shall mean the term of this Agreement. 

        "Territory" shall mean all of the countries of the world. 

        "Third Party Oligonucleotide Drug" shall mean any Oligonucleotide Drugs Controlled solely by an Independent Third Party, other than an
Isis Oligonucleotide Drug. 

4

 

        "Third Party Product" shall mean Products based upon Third Party Oligonucleotide Drugs that are made, designed, or otherwise created by or
on behalf of an Independent Third Party after the Effective Date using the Orasense Collaboration Intellectual Property and/or the Licensed Technologies. For avoidance of doubt, any Product based upon
an Oligonucleotide Drug jointly developed by an Independent Third Party and Isis other than pursuant to the Research Plan shall be deemed to be an
Isis Product; provided, however, that such Third Party Product does not incorporate or otherwise utilize Orasense Collaboration Intellectual Property or Elan Intellectual Property. 

        "Transaction Documents" means this Agreement, the Elan License Agreement, the Isis License Agreement, the Registration Rights Agreements
and associated documentation of even date herewith, by and between Isis, Elan, EIS and Orasense, as applicable. 

        "United States Dollar" and "US$" and "$"
means the lawful currency of the United States of America. 

        1.2  In
addition, the following definitions have the meanings in the Clauses corresponding thereto, as set forth below. 

	Definitions
 
	 	Clause

	"Buyout Option"	 	20.1
	"Closing"	 	4.2
	"Confidential Information"	 	22.1
	"EIS Director"	 	7.2
	"Elan Valuation"	 	20.2
	"Indemnified Party"	 	10.6
	"Isis Directors"	 	7.1
	"Isis Valuation"	 	20.2
	"Management Committee"	 	7.2.1
	"Presiding Justice"	 	20.2
	"Purchase Price"	 	20.2
	"R&D Committee"	 	7.2.2
	"Relevant Event"	 	21.2
	"Research Funding"	 	9.3
	"Transfer"	 	17.1

        1.3  Words
importing the singular shall include the plural and vice versa. 

        1.4  Unless
the context otherwise requires, reference to a recital, article, paragraph, provision, clause or schedule is to a recital, article, paragraph, provision, clause
or schedule of or to this Agreement. 

        1.5  Reference
to a statute or statutory provision includes a reference to it as from time to time amended, extended or re-enacted. 

        1.6  The
headings in this Agreement are inserted for convenience only and do not affect its construction. 

        1.7  Unless
the context or subject otherwise requires, references to words in one gender include references to the other genders. 

        1.8  Capitalized
terms used but not defined herein shall have the meanings ascribed in the Transaction Documents, if defined therein. 

5

 

CLAUSE 2  

 ORASENSE'S BUSINESS  

        2.1  The
primary objectives of Orasense is to carry on the business of the development, testing, registration, Commercialization and licensing of the Product and the
Development Product in the
Territory and to achieve the objectives set out in this Agreement and the License Agreements. The focus of the collaborative venture will be to develop the Oral Platform and Development Candidate
using the Elan Intellectual Property, the Isis Intellectual Property and the Orasense Collaboration Intellectual Property to agreed-upon specifications and timelines and to Commercialize a
Product and Development Product. 

        2.2  Except
as the Participants otherwise agree in writing and except as may be provided in this Agreement or the License Agreements, Isis and Orasense shall exercise their
respective powers in relation to Orasense so as to ensure that the Business is carried on in a proper and prudent manner. Elan shall fully cooperate with Orasense and Isis in this regard through the
end of the Research Term, and thereafter, at Elan's option and discretion. 

        2.3  Each
of Isis and Orasense shall use all commercially reasonable and proper means at its disposal and within its power to maintain, extend and improve the Business of
Orasense, within the limits of this Agreement, and to further the reputation and interests of Orasense. 

        2.4  The
central management and control of Orasense shall be exercised in Bermuda and shall be vested in the Directors and such Persons as they may delegate the exercise of
their powers in accordance with the Orasense Memorandum of Association and Bye-Laws. The Participants shall use their best endeavors to ensure that to the extent required pursuant to the
laws of Bermuda, and to ensure the sole residence of Orasense in Bermuda, all meetings of the Directors are held in Bermuda or other jurisdictions outside the United States and generally to ensure
that Orasense is treated as resident for taxation purposes in Bermuda. 

CLAUSE 3  

 REPRESENTATIONS AND WARRANTIES  

        3.1    Representations and Warranties of Orasense:    Orasense hereby represents and warrants to each of the
Stockholders as follows, as of the Original Effective Date: 

        3.1.1    Organization:    Orasense is an exempted company duly organized, validly existing and in good standing under
the laws of Bermuda, and has all the requisite corporate power and authority to own and lease its properties, to carry on its business as presently conducted and as proposed to be conducted, to
execute this Agreement, which has been duly authorized and is enforceable against Orasense in accordance with its terms, and to carry out the transactions contemplated hereby. 

        3.1.3    Authorization:    The execution, delivery and performance by Orasense of this Agreement, including the
issuance of the Shares, have been duly authorized by all requisite corporate actions; this Agreement has been duly executed and delivered by Orasense and is the valid and binding obligation of
Orasense, enforceable against it in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting the
enforcement of creditors' rights generally, and by general equity principles and limitations on the availability of equitable relief, including specific performance. The Shares, when issued as
contemplated hereby, will be validly issued and outstanding, fully paid and non-assessable and not subject to preemptive or any other similar rights of the Stockholders or others. 

6

 

        3.1.4    No Conflicts:    The execution, delivery and performance by Orasense of this Agreement, the issuance, sale
and delivery of the Shares, and compliance with the provisions hereof by Orasense, will not: 

        (i)    violate
any provision of applicable law, statute, rule or regulation applicable to Orasense or any ruling, writ, injunction, order, judgment or decree of any court,
arbitrator, administrative agency or other governmental body applicable to Orasense or any of its properties or assets; 

        (ii)  conflict
with or result in any breach of any of the terms, conditions or provisions of, or constitute (with notice or lapse of time or both) a default (or give rise to
any right of termination, cancellation or acceleration) under its charter or organizational documents or any material contract to which Orasense is a party, except where such violation, conflict or
breach would not, individually or in the aggregate, have a material adverse effect on Orasense; or 

        (iii)  result
in the creation of, any Encumbrance upon any of the properties or assets of Orasense, except as contemplated by the Transaction Documents. 

        3.1.5    Approvals:    As of the date hereof, no permit, authorization, consent or approval of or by, or any
notification of or filing with, any Person is required in connection with the execution, delivery or performance of this Agreement by Orasense. Orasense has full authority to conduct its business as
contemplated in the Research Plan and the Transaction Documents. 

        3.2    Representations and Warranties of the Stockholders:    Each of the Stockholders hereby severally represents and
warrants to Orasense as of the Original Effective Date, as follows: 

        3.2.1    Organization:    Such Stockholder is a corporation duly organized and validly existing under the laws of its
jurisdiction of organization and has all the requisite corporate power and authority to own and lease its respective properties, to carry on its respective business as presently conducted and as
proposed to be conducted and to carry out the transactions contemplated hereby. 

        3.2.2    Authority:    Such Stockholder has full corporate power and authority to enter into this Agreement and to
perform its obligations hereunder, which have been duly authorized by all requisite corporate action of such Stockholder. This Agreement is the valid and binding obligation of such Stockholder,
enforceable against it in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting the enforcement
of creditors' rights generally, and by general equity principles and limitations on the availability of equitable relief, including specific performance. 

        3.2.3    No Conflicts:    The execution, delivery and performance by such Stockholder of this Agreement, purchase of
the Shares and compliance with the provisions hereof by such Stockholder will not: 

          (i)  violate
any provision of applicable law, statute, rule or regulation known by and applicable to such Stockholder or any ruling, writ, injunction, order, judgment or
decree of any court, arbitrator, administrative agency or other governmental body applicable to such Stockholder or any of its properties or assets; 

        (ii)  conflict
with or result in any breach of any of the terms, conditions or provisions of, or constitute (with notice or lapse of time or both) a default (or give rise to
any right of termination, cancellation or acceleration) under the charter or organizational documents of such Stockholder or any material contract to which such Stockholder is a party, except where
such violation, conflict or breach would not, individually or in the aggregate, have a material adverse effect on such Stockholder; or 

7

  

        (iii)  result
in the creation of, any Encumbrance upon any of the properties or assets of such Stockholder, except as contemplated by the Transaction Documents. 

        3.2.4    Approvals:    As of the date hereof, no material permit, authorization, consent or approval of or by, or any
notification of or filing with, any Person is required in connection with the execution, delivery or performance of this Agreement by such Stockholder. 

        3.2.5    Investment Representations:    Such Stockholder is capable of evaluating the merits and risks of its
investment in Orasense. Such Stockholder has not been formed solely for the purpose of making this investment and such Stockholder is acquiring the Common Stock, if any, for investment for its own
account, not as a nominee or agent, and not with the view to, or for resale in connection with, any distribution of any part thereof. Such Stockholder understands that the Shares have not been
registered under the Securities Act or applicable state and foreign securities laws by reason of a specific exemption from the registration provisions of the Securities Act and applicable state and
foreign securities laws, the availability of which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of such Stockholders' representations as expressed
herein. Such Stockholder understands that no public market now exists for any of the Shares and that there is no assurance that a public market will ever exist for such Shares. 

        3.3    Survival:    The representations and warranties in this Clause 3 shall survive for a period of two years
from and after the date hereof. 

CLAUSE 4  

 AUTHORIZATION AND CLOSING  

        4.1  On
the Original Effective Date, Orasense authorized the issuance to (i) EIS of 2,388 shares of Common Stock and (ii) Isis of 9,612 shares of Common Stock,
issuable as provided in Clause 4.3 hereof 

        4.2  On
the Original Effective Date, Orasense issued and sold to EIS, and EIS purchased from Orasense, upon the terms and subject to the conditions set forth herein, 2,388
shares of Common Stock for an aggregate purchase price of $2,985,000. Orasense issued and sold to Isis, and Isis purchased from Orasense, upon the terms and conditions set forth herein, 9,612 shares
of Common Stock for an aggregate purchase price of $12,015,000. 

        4.3  [***]
The parties agree that they will take all action reasonably necessary, including amending the Orasense Memorandum of Association and
Bye-Laws to increase the number of shares reserved for issuance by Orasense, to ensure the issuance of the Stock contemplated by this Section 4.3. 

        4.4  A
closing shall take place in six month intervals (each, a "Closing") commencing [***] and will
be held at the offices of Isis at 2292 Faraday Avenue, Carlsbad, California 92008 or such other place if any, as the Parties may agree. 

        4.5  At
each Closing, 

        4.5.1    Orasense
shall issue and sell to the Stockholders the applicable number of shares, calculated pursuant to Section 4.3 above. 

        4.5.2  The
Parties shall execute and deliver to each other, as applicable, certificates in respect of the Common Stock described above and any other
certificates, resolutions or documents which the Parties shall reasonably require. 

8

 

        4.6    Exemption from Registration:    

        The
Shares will be issued under an exemption or exemptions from registration under the Securities Act. Accordingly, the certificates evidencing the Shares shall, upon issuance, contain
the following legend: 

        THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT UNDER ANY CIRCUMSTANCES BE SOLD, TRANSFERRED
OR OTHERWISE DISPOSED OF WITHOUT AN EFFECTIVE
REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION
IS NOT REQUIRED UNDER SUCH ACT OR APPLICABLE STATE SECURITIES LAWS.

        THE TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS ALSO SUBJECT TO THE RESTRICTIONS CONTAINED IN THAT CERTAIN AMENDED AND RESTATED SUBSCRIPTION,
JOINT DEVELOPMENT AND OPERATING AGREEMENT, DATED OCTOBER 14, 2002, BY AND AMONG ELAN CORPORATION, PLC, ELAN INTERNATIONAL SERVICES, INC., ISIS PHARMACEUTICALS, INC. AND
ORASENSE LTD.

CLAUSE 5  

 DELETED  

CLAUSE 6  

 NON-COMPETITION  

        6.1  From
the Original Effective Date and through [***], the Parties agree to be bound by the provisions of Clause 11 of the Elan License
Agreement and the provisions of Clause 11 of the Isis License Agreement, which set forth the agreement between the parties thereto in relation to the non-competition obligations of
Elan and Isis, respectively. 

CLAUSE 7  

 DIRECTORS; MANAGEMENT AND R&D COMMITTEES  

        7.1.    Directors:    

        The
Board of Directors of Orasense shall be composed of four Directors. Prior to an Elan Minority Interest, Isis shall have the right to nominate three directors of Orasense
("Isis Directors") and EIS shall have the right to nominate one Director of Orasense ("EIS Director");
provided that one such director is a resident of Bermuda. Isis may appoint one of the Isis Directors to be the chairman of Orasense. Each Participant agrees to vote its shares of Common Stock in favor
of the election of the nominees of the other Participant to the Board of Directors. 

        7.1.1  If
the chairman is unable to attend any meeting of the Board, the Isis Directors shall be entitled to appoint another Director to act as chairman in his
place at the meeting. 

        7.1.2  If
EIS removes the EIS Director, or Isis removes any of the Isis Directors, EIS or Isis, as the case may be, shall indemnify the other Stockholder
against any claim by such removed Director arising from such removal. 

9

 

        7.1.3  Prior
to an Elan Minority Interest, the Directors shall meet not less than three times in each Financial Year and all Directors' meetings shall be held
in Bermuda to the extent required pursuant to the laws of Bermuda or to ensure the sole residence of Orasense in Bermuda. 

        7.1.4  Prior
to an Elan Minority Interest, at any such meeting, the presence of the EIS Director and one of the Isis Directors shall be required to constitute a
quorum and after an Elan Minority Interest, a majority of the then acting directors will be required to constitute a quarum. Subject to Clause 18 hereof, the affirmative vote of a majority of
the Directors present at a meeting at which such a quorum is present shall constitute an action of the Directors. In the event of any meeting being inquorate, the meeting shall be adjourned for a
period of seven days. A notice shall be sent to the EIS Director and the Isis Directors specifying the date, time and place where such adjourned meeting is to be held and reconvened. 

        7.1.5  In
the event of an Elan Minority Interest, each of Isis, and EIS shall cause the board of Directors of Orasense to be reconfigured so that all of the
Directors are designated by Isis and EIS will lose its right to nominate any Directors of Orasense. 

        7.1.6  In
case of an equality of votes at a meeting of the board of Directors of Orasense, the chairman of Orasense shall not be entitled to a second or casting
vote. In the event of continued deadlock, the board of Directors shall resolve the deadlock pursuant to the provisions set forth in Clause 19. 

        7.2    Management and R&D Committees:    

        7.2.1  On
or about the Original Effective Date, the Directors appointed a management committee (the "Management
Committee") to perform certain operational functions, such delegation to be consistent with the Directors' right to delegate powers pursuant to the Orasense Memorandum of
Association of Bye-Laws. As of the Effective Date, the Management Committee consists of four members, two of whom will be nominated by EIS and two of whom will be nominated by Isis, and
each of whom shall be entitled to one vote. In the event of a Failure to Fund at any time after the end of the Research Term, EIS will lose its right to nominate members of the Management Committee
and Isis will be able to nominate all the members of the Management Committee, and each member will be entitled to one vote. The affirmative vote of at least 3 members of the Management Committee will
constitute an action of the Management Committee. 

        7.2.2  On
or about the Original Effective Date, the Management Committee appointed a research and development committee (the "R&D
Committee") which is comprised of four members, two of whom were nominated by Elan and two of whom were nominated by Isis, and each of whom have one vote. In the event of a
Failure to Fund at any time after the end of the Research Term, EIS will lose its right to nominate members of R&D Committee and Isis will be able to nominate all the members of the R&D Committee, and
each member will be entitled to one vote. The affirmative vote of at least 3 members of the R&D Committee will constitute an action of the R&D Committee. 

        7.2.3  The
Management Committee's responsibilities include, inter alia, devising, implementing and reviewing strategy for the business and operations of
Orasense, and in particular, devising Orasense's strategy for research and development and to monitor and supervise the implementation of Orasense's strategy for research and development. 

        7.2.4  The
R&D Committee is responsible for: 

        7.2.4.1  establishing
a joint Project team consisting of an equal number of team members from Elan and Isis, including one Project leader from each of Elan and
Isis, except after an Elan Minority Interest the joint project team will consist of all Isis team members; and 

10

 

        7.2.4.2  implementing
such portion of the Research Plan that relates to the Project, as approved by the Management Committee. 

        7.2.5  In
the event of any dispute amongst the R&D Committee, the R&D Committee shall refer such dispute to the Management Committee whose decision on the
dispute shall be binding on the R&D Committee. If the Management Committee cannot resolve the matter, the dispute will be referred to the President of Elan and the Chief Executive Officer of Isis
pursuant to Clause 19 hereof. 

        7.2.6  On
not more than [***] times in each Financial Year, Elan and Isis shall permit Orasense or its duly authorized representative on
reasonable notice and at any reasonable time during normal business hours to have access to inspect and audit the accounts and records of Elan or Isis and any other book, record, voucher, receipt or
invoice relating to the calculation or the cost of the Research Plan and to the accuracy of the reports which accompanied them. Any such inspection of Elan's or Isis's records, as the case may be,
shall be at the expense of Orasense, except that if such inspection reveals an overpayment in the amount paid to Elan or Isis, as the case may be, for the Research Plan hereunder in any Financial Year
of [***] or more of the amount due to Elan or Isis, as the case may be, then the expense of such inspection shall be borne solely by Elan or Isis, as the case may be, instead
of by Orasense. Any surplus over the sum properly payable by Orasense to Elan or Isis, as the case may be, shall be paid promptly by Elan or Isis, as the case may be, to Orasense. If such inspection
reveals a deficit in the amount of the sum properly payable to Elan or Isis, as the case may be, by Orasense, Orasense shall pay the deficit to Elan or Isis, as the case may be. 

CLAUSE 8  

 THE RESEARCH PLAN AND REVIEWS  

        8.1  The
Directors have met and agreed upon the Research Plan, including the applicable budget. Except for material modifications to the Research Plan, no additional approval
is needed from the Directors to carry out the Research Plan. 

        8.2  The
Participants agree that the Management Committee shall submit to the Directors on February 15th, May 15th, August 15th, and
November 15th or as soon as reasonably practicable thereafter in each Financial Year a report on the performance of the Business and research and development activities of
Orasense, and the Directors shall hold such meeting as may be necessary to review the performance of Orasense against the Research Plan for the relevant year. 

CLAUSE 9  

 RESEARCH AND DEVELOPMENT WORK; FUNDING  

        9.1  Orasense
will diligently pursue the research, development and Commercialization of the Elan Intellectual Property, Isis Intellectual Property and Orasense Intellectual
Property. During the Research Term, such work shall be agreed to and conducted by Elan and/or Isis under contract with Orasense as provided in the Research Plan. At the end of the Research Term, Isis
and Elan may decide by mutual written agreement to extend the Research Term and adopt a corresponding Research Plan. 

        9.2  During
the Research Term, Elan and Isis shall provide reasonable research and development services as may be reasonably required by Orasense in accordance with the
provisions in the License Agreements. Orasense shall pay Isis and Elan for any research and development work carried out by each of Isis and Elan on behalf of Orasense at the end of each month, and
any extension thereto, subject to the proper vouching of research and development work and expenses. An invoice shall be issued to Orasense by Isis or Elan, as applicable, by the 15th
day of the month following the month in 

11

 

which work was performed. The payments by Orasense to Isis or Elan, as the case may be, shall be at the rates prescribed in the respective License Agreement. Research and development activities that
are outsourced to third party providers shall be charged to Orasense at fully burdened actual costs. 

        9.3  Isis
and EIS agree to fund the Research Plan through the end of the Research Term pursuant to the budget attached to the Research Plan (the
"Research Funding") by contributing cash to Orasense, such funding to be provided on a pro rata basis in accordance with their respective ownership
interests in Orasense; [***] 

        9.4  The
Research Funding will be provided by EIS and Isis at such times as shall be necessary under the Research Plan, as shall be reasonably determined in good faith by the
decision of the Directors. 

        9.5  At
the end of the Research Term, EIS will have [***] days to notify Orasense in writing whether EIS wishes to continue funding the Research Plan.
If EIS fails to notify Orasense in writing within such [***]-day period of its decision to continue funding, then, notwithstanding anything contained herein to the
contrary, EIS will no longer be obligated to fund the Research Plan nor shall Elan be obligated to provide employees, services or other assistance to Orasense and a "Failure to Fund" will be deemed to
have occurred. In the event of a Failure to Fund, Isis may continue funding the Research Plan and will receive Shares as provided in Section 4 of this Agreement. 

        9.6  Reference
is made to Sections 2.4, 7.2.1, 7.2.2, 10.3, 16.1 and 18.2 of this Agreement and Section 12.5 of the Isis License Agreement with respect to certain
rights that will terminate after a Failure to Fund. 

CLAUSE 10  

 INTELLECTUAL PROPERTY RIGHTS  

        10.1 Title
and all other ownership rights, including patent rights, relating to the Orasense Intellectual Property shall belong to Orasense. Title and all other ownership
rights, including patent rights, relating to the Isis Intellectual Property shall belong to Isis. Title and all other ownership rights, including patent rights, relating to the Elan Intellectual
Property shall belong to Elan. Otherwise, title and all other ownership rights will belong to the Party inventing an invention. 

        10.2 Prior
to a Failure to Fund, the Participants shall discuss in good faith all material issues relating to filing, prosecution and maintenance of Patents within the
Orasense Intellectual Property insofar as such Patents are of relevance to the Field and any patentable inventions discovered by Elan, Isis or Orasense that relate to the Field and any patentable
improvements thereto. Subject to mutual agreement to the contrary by Isis and Elan the following provisions shall apply: 

        10.2.1  Orasense,
shall (i) file and prosecute patent applications on patentable inventions and discoveries within the Orasense Collaboration
Intellectual Property; (ii) defend all such applications against third party oppositions; and (iii) maintain in force any issued letters patent within the Orasense Intellectual Property
(including any patents that issue on patentable inventions and discoveries within the Orasense Intellectual Property). Orasense shall control such filing, prosecution, defense and maintenance. 

        10.2.2  Orasense,
Elan and Isis shall promptly inform each other in writing of any alleged infringement of any Patents within the Elan Intellectual Property,
the Isis Intellectual Property or the Orasense Collaboration Intellectual Property or any alleged misappropriation of trade secrets within the Elan Intellectual Property, the Isis Intellectual
Property or the Orasense Collaboration Intellectual Property by a third party of which it becomes aware and provide the Participants and Orasense with any available evidence of such infringement or
misappropriation insofar as such infringements or misappropriation relate solely to the Field. 

12

 

        10.3 Orasense
shall have the first right but not the obligation to bring suit or otherwise take action against any alleged infringement of the Orasense Intellectual Property
or alleged misappropriation of the Orasense Intellectual Property. If any such alleged infringement or misappropriation occurs that gives rise to a cause of action both inside and outside the Field,
Orasense, in consultation with the Participants, shall determine the cause of action to be taken. In the event that Orasense takes such action, Orasense shall do so at its own cost and expense and all
damages and monetary award recovered in or with respect to such action shall be the property of Orasense. Orasense shall keep Elan and Isis informed of any action in a timely manner so as to enable
Isis and Elan to provide input in any such action and Orasense shall reasonably take into consideration any such input. At Orasense's request, the Participants shall cooperate with any such action at
Orasense's cost and expense. 

        10.4 In
the event that Orasense does not bring suit or otherwise take action against all infringement of the Orasense Intellectual Property or misappropriation of the
Orasense Intellectual Property, then (i) if only one Participant determines to pursue such suit or take such action at its own cost and expense, it shall be entitled to all damages and monetary
award recovered in or with respect to such action and (ii) if the Participants pursue such suit or action outside of Orasense, they shall negotiate in good faith an appropriate allocation of
costs, expenses and recovery amounts. 

        10.5 In
the event that a claim is, or proceedings are, brought against Orasense by a third party alleging that the sale, distribution or use of a Product in the Territory or
use of the Orasense Intellectual Property or the Isis Intellectual Property, as the case may be, infringes the intellectual property rights of such party, Orasense shall promptly advise the other
Participants of such threat or suit. 

        10.6 Orasense
and Isis and any of their respective sublicensees shall indemnify, defend and hold harmless Elan and its Affiliates, and each of Elan's and its Affiliates'
respective employees, agents, partners, officers and directors (each an "Indemnified Party") against all actions, losses, claims, demands, damages,
costs and liabilities (including reasonable attorneys fees) relating directly or indirectly to all such claims or proceedings referred to in Clause 10.4 above, provided that Elan shall not
acknowledge to the third party or to any other person the validity of any claims of such a third party, and shall not compromise or settle any claim or proceedings relating thereto without the prior
written consent to Orasense, not to be unreasonably withheld or delayed. At its option, Elan or Isis, as the case may be, may elect to take over the conduct of such proceedings from Orasense provided
that Orasense's indemnification obligations shall continue; the costs of defending such claim shall be borne by Elan or Isis, as the case may be and such Participant shall not compromise or settle any
such claim or proceeding without the prior written consent of Orasense, such consent not to be unreasonably withheld or delayed. 

        10.7 Orasense
shall not encumber any of its rights under the Licenses (except as permitted therein and in Section 12.2 hereof) or the Orasense Intellectual Property
without the prior written consent of Elan and Isis; provided that after a Failure to Fund, Elan's consent rights with respect to the Isis License and Orasense Post-Collaboration Property
will no longer be required. Orasense shall not be permitted to assign or sublicense any of its rights under the Licenses (except as expressly provided under the Elan License Agreement and Isis License
Agreement) or the Orasense Intellectual Property without the prior written consent of Elan and Isis, respectively, which may be withheld in Elan's or Isis' sole
discretion, as the case may be; provided that after a Failure to Fund, Elan's consent rights with respect to the Isis License or Orasense Post-Collaboration Intellectual Property will no
longer be required. 

13

 

CLAUSE 11  

 UNBLOCKING LICENSES  

        11.1 Isis
and its Affiliates shall secure the right to sublicense to Elan any Isis Blocking Invention made by Isis, Orasense or any of their respective Affiliates and/or
sublicensees or any Independent Third Party under contract with Isis, Orasense or any of their respective Affiliates and/or sublicensees. Isis hereby grants to Elan a royalty free,
world-wide, irrevocable, [***] license, including the right to grant sublicenses, to research, develop, make and have made, offer for sale, sell, import and export
products incorporating the Isis Blocking [***] to practice the Elan Intellectual Property and/or Orasense Intellectual Property to the extent same could not otherwise be
practiced without first obtaining a license to such Isis Blocking Invention. 

        11.2 Orasense
and its Affiliates shall secure the right to sublicense to Elan any Orasense Blocking Invention made by Isis, Orasense or any of their respective Affiliates
and/or sublicensees or any Independent Third Party under contract with Isis, Orasense or any of their respective Affiliates and/or sublicensees. Isis hereby grants to Elan a royalty free,
world-wide, irrevocable, [***] license, including the right to grant sublicenses, to research, develop, make and have made, offer for sale, sell, import and export
products incorporating the Isis Blocking Inventions [***] to practice the Elan Intellectual Property and/or Orasense Intellectual Property to the extent same could not
otherwise be practiced without first obtaining a license to such Isis Blocking Invention. 

        11.3 Orasense
and Isis and each of their respective Affiliates will [***] efforts to exclude or, where applicable, minimize royalty or other
compensation obligations in respect of any Isis Blocking Invention and/or Orasense Blocking Invention, as the case may be. Elan will be responsible for the payment of such royalty or other
compensation obligations triggered by Elan's practice and use of the Isis Blocking Invention and/or Orasense Isis Blocking Invention, as the case may be, solely to the extent a royalty or other
compensation obligation to Independent Third Parties are payable with respect to Elan's use of an Isis Blocking Invention and/or Orasense Blocking Invention, as the case may be;  provided, however, that
any royalty or other compensation obligations payable by Elan to such Independent Third Parties under such license shall be
substantially similar to the royalty obligations or other compensation obligations payable by Isis and/or Orasense in connection with any license to an invention or discovery and Patents that may
issue thereon that would prevent Isis and or Orasense from practicing the Elan
Intellectual Property and/or the Orasense Collaboration Intellectual Property licensed to such Independent Third Party, but for such license. 

CLAUSE 12  

 COMMERCIALIZATION  

        12.1 The
Participants shall, during the Research Term, assist Orasense in diligently pursuing the research, development, prosecution and commercialization of Products in
accordance with the Research Plan. 

        12.2 During
and following the Research Term, Isis as an agent for Orasense, may negotiate and execute with Independent Third parties regarding a license and collaboration
agreement for developing and Commercializing the Development Candidate. By executing this Agreement, Elan, and its nominees on the Board and its nominees on the Management Committee authorize Isis and
Orasense to conduct such negotiation and to execute any agreement that may arise therefrom. 

        12.3 In
the event an Independent Third Party shall propose to Orasense the development of Third Party Products, the Management Committee, by unanimous decision, shall
determine whether or not to develop any such Third Party Product. Orasense shall be responsible for negotiating with any 

14

 

Independent Third Parties commercially reasonable terms (e.g., royalties, milestones, development fees, manufacturing rights) for developing and licensing Third Party Products. 

CLAUSE 13  

 MANUFACTURING  

        13.1 Isis
will notify Elan in writing of Isis' good faith intention to manufacture or have manufactured an Oligonucleotide Drug incorporating any Elan Intellectual Property.
Elan will have [***] from the receipt of such notice to notify Isis in writing whether or not Elan wishes to negotiate with Isis regarding the manufacture of the
Oligonucleotide Drug. If Elan fails to respond to Isis' notice within the [***] or if Elan declines in writing to exercise its right of first negotiation, then, Isis will be
free to manufacture and supply (either on its own or with a third party) the Oligonucleotide Drug. If Elan wishes to manufacture the Oligonucleotide Drug incorporating any Elan Intellectual Property,
the parties will negotiate in good faith the terms of a manufacturing agreement. If despite good faith negotiations, Elan and Isis do not reach agreement within [***] from
Elan's exercise of its right of first negotiation, then Isis will be free to manufacture and supply (either on its own or with a third party) the Oligonucleotide Drug. 

CLAUSE 14  

 TECHNICAL SERVICES AND ASSISTANCE  

        14.1 Whenever
commercially and technically feasible, Orasense shall contract with Isis or Elan, as the case may be, to perform such other services as Orasense may require,
other than those specifically dealt with hereunder or in the License Agreements. In determining which Party should provide such services, the Management Committee shall take into account the
respective infrastructure, capabilities and experience of Elan and Isis. 

        14.2 The
Parties agree that each Party shall effect and maintain comprehensive general liability insurance under industry standard insurance policies in respect of all
clinical trials and other activities performed by them on behalf of Orasense. 

        14.3 If
Elan or Isis so requires, Isis or Elan, as the case may be, shall receive, at times and for periods mutually acceptable to the Parties, employees of the other Party
(such employees to be acceptable to the receiving Party in the matter of qualification and competence) for instruction in respect of the Elan Intellectual Property or the Isis Intellectual Property,
as the case may be, as necessary to further the Research Plan. 

        14.4 The
employees received by Elan or Isis, as the case may be, shall be subject to obligations of confidentiality no less stringent than those set out in Clause 22
and such employees shall observe the rules, regulations and systems adopted by the Party receiving the said employees for its own employees or visitors. 

CLAUSE 15  

 AUDITORS, BANKERS, REGISTERED OFFICE,

ACCOUNTING REFERENCE DATE; SECRETARY; COUNSEL  

        Unless otherwise agreed by the Stockholders and save as may be provided to the contrary herein: 

        15.1 the
auditors of Orasense shall be Ernst & Young; 

        15.2 the
bankers of Orasense shall be Bank of Bermuda or such other bank as may be agreed by the Directors from time to time; 

15

   
        15.3 the accounting reference date of Orasense shall be December 31st in each Financial Year; and 

        15.4 the
secretary of Orasense shall be Diana Martin or such other Person as may be appointed by the Directors from time to time. 

CLAUSE 16  

 REGULATORY  

        16.1 Orasense
shall keep the other Parties promptly and fully advised of Orasense's regulatory activities, progress and procedures; provided, however, that Elan's rights
hereunder will terminate after a Failure to Fund, except as is otherwise set forth under the Elan License Agreement. Orasense shall inform the other Parties of any dealings it shall have with a
Regulatory Authority, and shall furnish the other Parties with copies of all correspondence relating to the Products. The Parties shall collaborate to obtain any required regulatory approval of the
Regulatory Authority to market the Products. 

        16.2 Orasense
shall, at its own cost, file, prosecute and maintain any and all Regulatory Applications for the Products in the Territory in accordance with the Research
Plan. 

        16.3 Any
and all Regulatory Approvals obtained hereunder for any Product shall remain the property of Orasense, provided that Orasense shall allow Elan and Isis access
thereto to enable Elan and Isis to fulfill their respective obligations and exercise their respective rights under this Agreement. Orasense shall maintain such Regulatory Approvals at its own cost. 

        16.4 It
is hereby acknowledged that there are inherent uncertainties involved in the registration of pharmaceutical products with the Regulatory Authorities insofar as
obtaining approval is concerned and
such uncertainties form part of the business risk involved in undertaking the form of commercial collaboration as set forth in this Agreement. Therefore, except for liabilities resulting from failure
to use reasonable efforts, none of Elan, EIS or Isis shall have any liability to Orasense solely as a result of any failure of a Product to achieve the approval of any Regulatory Authority. 

CLAUSE 17  

 TRANSFERS OF SHARES  

        17.1    General:    

        No
Stockholder shall, directly or indirectly, sell or otherwise transfer (each, a "Transfer") any Shares held by it except in accordance
with this Agreement. Orasense shall not, and shall not permit any transfer agent or registrar for any Shares to, transfer upon the books of Orasense any Shares from any Stockholder to any transferee,
in any manner, except in accordance with this Agreement, and any purported transfer not in compliance with this Agreement shall be void. 

CLAUSE 18  

 MATTERS REQUIRING PARTICIPANTS' APPROVAL  

        18.1 In
consideration of Isis and Elan agreeing to enter into the License Agreements, the Parties hereby agree that Orasense shall not without the prior approval of the EIS
Director and at least two of the Isis Directors: 

        18.1.1.  issue
any unissued Shares or create or issue any new shares, except as expressly permitted by the Orasense Bylaws and as contemplated under this
Agreement; 

        18.1.2.  alter
any rights attaching to any class of share in the capital of Orasense or alter the Orasense Memorandum of Association and Bye-Laws; 

16

 

        18.1.3.  consolidate,
sub-divide or convert any of Orasense's share capital or in any way alter the rights attaching thereto; 

        18.1.4.  dispose
of Orasense or of any shares in Orasense; 

        18.1.5.  do
or permit or suffer to be done any act or thing whereby Orasense may be wound up (whether voluntarily or compulsorily), save as otherwise expressly
provided for in this Agreement; 

        18.1.6.  enter
into any material contract or transaction except in the ordinary and proper course of the Business on arm's length terms, or as contemplated by
the Research Plan; 

        18.1.7.  alter
the number of Directors; 

        18.1.8.  change
the domicile of Orasense from Bermuda; 

        18.1.9.  register
any stock of Orasense with any governmental authority for public trading in any securities market; 

        18.1.10.  pay
dividends or distributions in respect of, or redeem or repurchase, the equity of Orasense; or 

        18.1.11.  adopt
or register or use any trade name, trademark or service mark on behalf of Orasense. 

        18.2 In
the event of a Failure to Fund, items 18.1.4, 18.1.6, 18.1.9 and 18.1.10 will be of no further force and effect. In the event of an Elan Minority Interest, all of
the rights under Section 18.1 will be of no further force or effect. 

CLAUSE 19  

 DISPUTES  

        19.1 Should
any dispute or difference arise between Elan and Isis, or between Elan or Isis and Orasense, during the period that this Agreement is in force, other than a
dispute or difference relating to (i) the interpretation of any provision of this Agreement, (ii) the interpretation or application of law, or (iii) the ownership of any
intellectual property, then any Party may forthwith give notice to the other Parties that it wishes such dispute or difference to be referred to the Chief Executive Officer of Isis and the President
of Elan. 

        19.2 In
any event of a notice being served in accordance with Clause 19.1, each of the Participants shall within 14 days of the service of such notice prepare
and circulate to the Chief Executive Officer of Isis and the President of Elan a memorandum or other form of statement setting out its position on the matter in dispute and its reasons for adopting
that position. Each memorandum or statement shall be considered by the Chief Executive Officer of Isis and the President of Elan who shall endeavor to resolve the dispute. If the chief executive
officers of the Participants agree upon a resolution or disposition of the matter, they shall each sign a statement which sets out the terms of their agreement. The Participants agree that they shall
exercise the voting rights and other powers available to them in relation to Orasense to procure that the agreed terms are fully and promptly carried into effect. 

CLAUSE 20  

 BUYOUT  

        20.1 After
Elan's ownership interest in Orasense fall's below [***] Isis shall have the right to purchase the shares of Orasense Common Stock held by
Elan (the "Buyout Option"), or its Affiliates 

17

 

for the stock's then fair market value, as determined by senior officers of Elan and Isis. Isis will notify Elan in writing of its decision to purchase such shares. 

        20.2 In
the event that the Participants do not agree upon a purchase price for the Shares within [***] Business Days following the receipt by Isis of
written notice from Elan pursuant to Clause 20.1 above, the Participants shall jointly select a nationally recognized investment banking firm as arbitrator to make such determination. In the
event the Participants do not agree upon the selection of such investment banking firm, Elan may contact the presiding justice of the Supreme Court of the State of New York sitting in the City,
County, and State of New York (the "Presiding Justice") and request that an independent US-based nationally recognized investment banking
firm which is knowledgeable of the pharmaceutical/biotechnology industry be appointed within 10 Business Days. The Presiding Justice shall endeavor to select an investment banking firm as arbitrator
which is technically knowledgeable in the pharmaceutical/biotechnology industry (and which directly and through its Affiliates, has no business relationship with, or shareholding in, either of the
Participants). Promptly upon being notified of the arbitrator's appointment, the Participants shall submit to the arbitrator details of their assessment [***] together with
such information as they think necessary to validate their assessment. The arbitrator shall notify Isis of the [***] and shall notify Elan of [***] The
Participants shall then be entitled to make further submissions to the arbitrator within five Business Days explaining why the proposed valuations, as the case may be, are unjustified. The arbitrator
shall thereafter meet with Isis and Elan and shall thereafter choose either [***] on the basis of [***] The arbitrator shall use its best efforts to
determine the [***] within 30 Business Days of his appointment. The Participants shall bear the costs of the arbitrator equally provided that the arbitrator may, in its
discretion, allocate all or a portion of such costs to one Party. Any decision of the arbitrator shall be final and binding. 

        20.3 Isis
shall purchase the Shares beneficially owned by Elan by delivery of the Purchase Price in cash no later than the 15th Business Day following determination of the
Purchase Price by the arbitrator. 

        20.4 The
Shares so transferred shall be sold by Elan with effect from the date of such transfer free from any lien, charge or encumbrance, but with all rights and
restrictions attaching thereto. 

        20.7 If
Isis exercises the Buyout Option, the provisions of Clauses 1, 3, 10.1, 10.3, 10.4, 10.5, 10.6, 11, 19, 20.7, 21, 22, 23 and 24 shall survive the termination of this
Agreement under this Clause 20.7; all other terms and provisions of this Agreement shall cease to have effect and be null and void. 

CLAUSE 21  

 TERMINATION  

        21.1 This
Agreement shall govern the operation and existence of Orasense until (i) terminated by written agreement of all Parties hereto or (ii) otherwise
terminated in accordance with this Clause 21. 

        21.2 For
the purpose of this Clause 21, a "Relevant Event" is committed or suffered by a Participant if: 

        21.2.1  it
commits a material breach of its obligations under this Agreement or the applicable License, which breach remains uncured
[***] after written notice thereof; provided, however, that (x) if the breaching Participant has proposed a course of action to rectify the breach and is acting in good
faith to rectify same but has not cured the breach by the [***], such period shall be extended by such period as is reasonably necessary to permit the breach to be rectified
and (y) if a default involves a good faith dispute regarding the amount of any required payment, provided any undisputed amount is paid, such default shall be stayed and the remainder may be
withheld for a reasonable period during which a good faith resolution of the amount owed is being pursued; 

18

 

        21.2.2  a
distress, execution, sequestration or other process is levied or enforced upon or sued out against a material part of its property which is not
discharged or challenged within 30 days; 

        21.2.3  it
is unable to pay its debts in the normal course of business; 

        21.2.4  it
ceases wholly or substantially to carry on its business, otherwise than for the purpose of a reconstruction or amalgamation, without the prior
written consent of the other Participant (such consent not to be unreasonably withheld); 

        21.2.5  the
appointment of a liquidator, receiver, administrator, examiner, trustee or similar officer of such Participant or over all or substantially all of
its assets under the law of any applicable jurisdiction, including without limitation, the United States of America, Bermuda or Ireland; 

        21.2.6  an
application or petition for bankruptcy, corporate re-organization, composition, administration, examination, arrangement or any other
procedure similar to any of the foregoing under the law of any applicable jurisdiction, including without limitation, the United States of America, Bermuda or Ireland, is filed, and is not discharged
within 60 days, or a Participant applies for or consents to the appointment of a receiver, administrator, examiner or similar officer of it or of all or a material part of its assets, rights or
revenues or the assets and/or the business of a Participant are for any reason seized, confiscated or condemned. 

        21.3 If
either Participant commits a Relevant Event, the other Stockholder shall have in addition to all other legal and equitable rights and remedies hereunder, the right
to terminate this Agreement upon 30 days' written notice. 

        21.4 In
the event of a termination of the Elan License Agreement and/or the Isis License Agreement, both parties will negotiate in good faith to determine whether this
Agreement should be terminated and if so, which provisions should survive termination. 

        21.5 The
provisions of Clauses 1, 3, 10.1, 10.3, 10.4, 10.5, 10.6, 11, 19, 20.7, 21, 22, 23 and 24 shall survive the termination of this Agreement under Clause 21.3
or by mutual consent pursuant to Clause 21.1 in accordance with their terms; all other terms and provisions of this Agreement shall cease to have effect and be null and void upon the
termination of this Agreement under Clause 21.3 or by mutual consent pursuant to Clause 21.1. 

CLAUSE 22  

 CONFIDENTIALITY  

        22.1 The
Parties acknowledge that it may be necessary, from time to time, to disclose to each other confidential and proprietary information, including without limitation,
Patents, inventions, works of authorship, trade secrets, specifications, designs, data, Know-How and other information relating to the Field, the Products, Elan Intellectual Property, Isis
Intellectual Property and Orasense Intellectual Property, as the case may be, processes, services and business of the disclosing Party. The foregoing shall be referred to collectively as
"Confidential Information". Any Confidential Information revealed by a Party to another Party shall be used by the receiving Party exclusively for the
purposes of fulfilling the receiving Party's obligations under this Agreement and the Development Agreement and for no other purpose. 

        22.2 Each
Party agrees to disclose Confidential Information of another Party only to those employees, representatives and agents requiring knowledge thereof in connection
with their duties directly related to the fulfilling of the Party's obligations under this Agreement. Each Party further agrees to inform all such employees, representatives and agents of the terms
and provisions of this Agreement and their duties hereunder and to obtain their consent hereto as a condition of receiving 

19

 

Confidential Information. Each Party agrees that it will exercise the same degree of care, but in no event less than a reasonable degree and protection to preserve the proprietary and confidential
nature of the Confidential Information disclosed by a Party, as the receiving Party would exercise to preserve its own proprietary and confidential information. Each Party agrees that it will, upon
request of a Party, return all documents and any copies thereof containing Confidential Information belonging to or disclosed by, such Party. 

        22.3 Notwithstanding
the above, each Party may use or disclose Confidential Information disclosed to it by another party to the extent such use or disclosure is reasonably
necessary in filing or prosecuting patent applications, prosecuting or defending litigation, complying with patent applications, complying with applicable governmental regulations or otherwise
submitting information to tax or other governmental authorities, conducting clinical trials, or making a permitted sub-license or otherwise exercising its rights hereunder, provided that
if a Party is required to make any such disclosure of the other Party's Confidential Information, other than pursuant to a confidentiality agreement, such Party shall inform the recipient of the terms
and provisions of this Agreement and their duties hereunder and to obtain their consent hereto as a condition of receiving Confidential Information. 

        22.4 Any
breach of this Clause 22 by any of the Persons informed by one of the Parties is considered a breach by the Party itself. 

        22.5 Confidential
Information shall not be deemed to include: 

        22.5.1  information
that is generally available to the public; 

        22.5.2  information
which is made public by the disclosing Party; 

        22.5.3  information
which is independently developed by a Party as evidenced by such Party's written records, without the aid, application or use of the
disclosing Party's Confidential Information; 

        22.5.4  information
that is published or otherwise becomes part of the public domain without any disclosure by a Party, or on the part of a Party's directors,
officers, agents, representatives or employees; 

        22.5.6  information
that becomes available to a Party on a non-confidential basis, whether directly or indirectly, from a source other than a Party,
which source did not acquire this information on a confidential basis; 

        22.5.7  information
that becomes available to a Party on a non-confidential basis, whether directly or indirectly, from a source other than a Party,
which source did not acquire this information on a confidential basis; 

        22.5.8  information
which the receiving Party is required to disclose pursuant to; 

        22.5.8.1  a
valid order of a court or other governmental body or any political subdivision thereof or otherwise required by law; or 

        22.5.8.2  any
other requirement of law; 

provided
that if the receiving Party becomes legally required to disclose any Confidential Information, the receiving Party shall give the disclosing Party prompt notice of such fact so that the
disclosing Party may obtain a protective order or other appropriate remedy concerning any such disclosure. The receiving Party shall fully cooperate with the disclosing Party in connection with the
disclosing Party's efforts to obtain any such order or other remedy. If any such order or other remedy does not fully preclude disclosure, the receiving Party shall make such disclosure only to the
extent that such disclosure is legally required; 

20

 

        22.5.9  information
which was already in the possession of the receiving Party at the time of receiving such information, as evidenced by its written records,
provided such information was not previously provided to the receiving Party from a source which was under an obligation to keep such information confidential; and 

        22.5.10  information
that is the subject of a written permission to disclose, without restriction or limitation, by the disclosing Party. 

        22.6 The
provisions relating to confidentiality in this Clause 22 shall remain in effect during the term of this Agreement, and for a period of seven (7) years
following the expiration or ea4lrier termination of this Agreement but shall not apply to any information which a Party is required to file or otherwise disclose in accordance with requirements which
are legally binding on it. 

        22.7 The
Parties agree that the obligations of this Clause 22 are necessary and reasonable in order to protect the Parties' respective businesses, and each Party
expressly agrees that monetary damages would be inadequate to compensate a Party for any breach by the other Party of its covenants and agreements set forth herein. Accordingly, the Parties agree and
acknowledge that any such violation or threatened violation will cause irreparable injury to a Party and that, in addition to any other remedies that may be available, in law and equity or otherwise,
any Party shall be entitled to obtain injunctive relief against the threatened breach of the provisions of this Clause 22, or a continuation of any such breach by the other Party, specific
performance and other equitable relief to redress such breach together with its damages and reasonable counsel fees and expenses to enforce its rights hereunder, without the necessity of proving
actual or express damages. 

        22.8 Each
of the Parties shall be entitled to provide a copy of this Agreement (and any subsequent amendments hereto) and the License Agreements to a potential third party
purchaser in connection with the sale of such Party's business or assets, including without limitation, in the case of Elan, the sale of the Elan Intellectual Property; provided that the relevant
third party purchaser or assignee has entered into a confidentiality agreement on terms no less protective than the terms of this Clause 22. 

CLAUSE 23  

 COSTS  

        23.1 Each
Stockholder shall bear its own legal and other costs incurred in relation to preparing and concluding this Agreement and the other Transaction Documents. 

        23.2 All
other costs, legal fees, registration fees and other expenses relating to the transactions contemplated hereby, including the costs and expenses incurred in
relation to the incorporation of Orasense, shall be borne by Orasense. 

CLAUSE 24  

 GENERAL  

        24.1    Good Faith:    

        Each
of the Parties hereto undertakes with the others to do all things reasonably within its power that are necessary or desirable to give effect to the spirit and intent of this
Agreement. 

        24.2    Further Assurance:    

        At
the request of any of the Parties, the other Party or Parties shall (and shall use reasonable efforts to procure that any other necessary parties shall) execute and perform all such
documents, acts and things as may reasonably be required subsequent to the signing of this Agreement for assuring to or vesting in the requesting Party the full benefit of the terms hereof. 

21

 

        24.3    Reliance on Representation and Warranties:    

        Each
of the Parties hereto hereby acknowledges that in entering into this Agreement it has not relied on any representation or warranty except as expressly set forth herein or in any
document referred to herein. 

        24.4    Force Majeure:    

        Neither
Party to this Agreement shall be liable for delay in the performance of any of its obligations hereunder if such delay is caused by or results from causes beyond its reasonable
control, including without limitation, acts of God, fires, strikes, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances
or intervention of any relevant government authority, but any such delay or failure shall be remedied by such Party as soon as practicable. 

        24.5    Relationship of the Parties:    

        Nothing
contained in this Agreement is intended or is to be construed to constitute Elan/EIS and Isis as partners, or Elan/EIS as an employee or agent of Isis, or Isis as an employee or
agent of Elan/EIS. 

        No
Party hereto shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of another Party or to bind another Party to any
contract, agreement or undertaking with any third Party. 

        24.6    Counterparts:    

        This
Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute this
Agreement. 

        24.7    Notices:    

        Any
notice to be given under this Agreement shall be sent in writing by registered or recorded delivery post or reputable overnight courier such as Federal Express or telecopied to: 

	If to Orasense at:	 	Orasense Ltd.

c/o Isis Pharmaceuticals, Inc.

2292 Faraday Avenue

Carlsbad, California 92008
	 	 	Attention:	 	Ms. Lynne Parshall
	 	 	Telephone:	 	(760) 603-2460
	 	 	Telefax:	 	(760) 931-9639
	

If to Isis to:	
 	

Isis Pharmaceuticals, Inc.

2292 Faraday Avenue

Carlsbad, California 92008
	 	 	Attention:	 	Ms Lynne Parshall
	 	 	Telephone:	 	(760) 603-2460
	 	 	Telefax:	 	(760) 931-9639
	

with a copy to:	
 	

Isis Pharmaceuticals, Inc.

2292 Faraday Avenue

Carlsbad, CA 92008
	 	 	Attention:	 	Grantland E. Bryce
	 	 	Telephone:	 	760-603-2707
	 	 	Fax:	 	760-268-4922

22

 

	

If to Elan at:	
 	

Elan Corporation, plc

C/o Elan International Services, Ltd.

102 St. James Court

Flatts,

Smiths FL04

Bermuda
	 	 	Attention:	 	Secretary
	 	 	Telephone:	 	441 292 9169
	 	 	Fax:	 	441 292 2224

        with
a copy to each of Isis, EIS and their respective counsel at the addresses indicated above; 

        or
to such other address(es) as may from time to time be notified by any Party to the others hereunder. 

        Any
notice sent by mail shall be deemed to have been delivered within three Business Days after dispatch or delivery to the relevant courier and any notice sent by telecopy shall be
deemed to have been delivered upon confirmation of receipt by telephone. Notices of change of address shall be effective upon receipt. 

        24.8    Governing Law    

        This
Agreement shall be governed by and construed in accordance with the laws of the State of New York without giving effect to any choice or conflict or law provision or rule. 

        24.9    Arbitration    

        (a)  Any
dispute under this Agreement or the other Transaction Documents which is not settled by mutual consent (whether pursuant to the provisions in Clause 19 hereof
or otherwise) shall be finally settled by binding arbitration, conducted in accordance with the Commercial Arbitration Rules of the American Arbitration Association by one (1) arbitrator
appointed in accordance with said rules. Such arbitrator shall be reasonably satisfactory to each of the Parties; provided, that if the Parties are unable to agree upon the identity of such arbitrator
within 15 days of demand by either Party, then either Party shall have the right to petition the Presiding Justice to appoint an arbitrator. 

        The
arbitration shall be held in New York, New York and the arbitrator shall be an independent expert in pharmaceutical product development and marketing (including clinical development
and regulatory affairs). 

        (b)  The
arbitrator shall determine what discovery will be permitted, consistent with the goal of limiting the cost and time which the Parties must expend for discovery;
provided the arbitrator shall permit such discovery as they deem necessary to permit an equitable resolution of the dispute. 

        Any
written evidence originally in a language other than English shall be submitted in English translation accompanied by the original or a true copy thereof. 

        The
costs of the arbitration, including administrative and arbitrators' fees, shall be shared equally by the Parties and each Party shall bear its own costs and attorneys' and witness'
fees incurred in connection with the arbitration. 

        (c)  In
rendering judgment, the arbitrator shall be instructed by the Parties that he shall be permitted to select solely from between the proposals for resolution of the
relevant issue presented by each Party, and not any other proposal. 

        A
disputed performance or suspended performances pending the resolution of the arbitration must be completed within thirty (30) days following the final decision of the
arbitrators or such other reasonable period as the arbitrators determine in a written opinion. 

23

 

        (d)  Any
arbitration under the Transaction Documents shall be completed within one year from the filing of notice of a request for such arbitration. 

        The
arbitration proceedings and the decision shall not be made public without the joint consent of the Parties and each Party shall maintain the confidentiality of such proceedings and
decision unless otherwise permitted by the other Party. 

        (e)  The
Parties agree that the decision shall be the sole, exclusive and binding remedy between them regarding any and all disputes, controversies, claims and counterclaims
presented to the arbitrators. Application may be made to any court having jurisdiction over the Party (or its assets) against whom the decision is rendered for a judicial recognition of the decision
and an order of enforcement. 

        24.10    Severability:    

        If
any provision in this Agreement is agreed by the Parties to be, deemed to be or becomes invalid, illegal, void or unenforceable under any law that is applicable hereto, such provision
will be deemed amended to conform to applicable laws so as to be valid and enforceable or, if it cannot be so amended without materially altering the intention of the Parties, it will be deleted, with
effect from the date of such agreement or such ea4lrier date as the Parties may agree, and the validity, legality and enforceability of the remaining provisions of this Agreement shall not be impaired
or affected in any way. 

        24.11    Amendments:    

        No
amendment, modification or addition hereto shall be effective or binding on any Party unless set forth in writing and executed by a duly authorized representative of all Parties. 

        24.12    Waiver:    

        No
waiver of any right under this Agreement shall be deemed effective unless contained in a written document signed by the Party charged with such waiver, and no waiver of any breach or
failure to perform shall be deemed to be a waiver of any future breach or failure to perform or of any other right arising under this Agreement. 

        24.13    Assignment:    

        None
of the Parties shall be permitted to assign its rights or obligations hereunder without the prior written consent of the other Parties except as follows: 

        24.13.1  Elan,
EIS and/or Isis shall have the right to assign their rights and obligations hereunder to their Affiliates provided, however, that such assignment
does not result in adverse tax consequences for any other Parties. 

        24.13.2  Elan
and EIS shall have the right to assign their rights and obligations hereunder to an off-balance sheet special purpose entity
established by Elan or EIS. 

        24.13.3  Elan,
EIS and/or Isis shall have the right to assign or otherwise transfer their rights and obligations hereunder in connection with a sale of all or
substantially all of the business of such Party to which the transaction Documents relate, whether by merger, sale of stock, sale of assets or otherwise; provided however, that Elan or EIS may not
assign or otherwise transfer (including by merger, sale of stock or sale of assets) its rights to fund Orasense or extend the Research Term. 

        24.14    Whole Agreement/No Effect on Other Agreements:    

        This
Agreement (including the Schedules attached hereto) and the other Transaction Documents set forth all of the agreements and understandings between the Parties with respect to the
subject 

24

 

matter hereof, and supersedes and terminates all prior agreements and understandings between the Parties with respect to the subject matter hereof. There are no agreements or understandings with
respect to the subject matter hereof, either oral or written, between the Parties other than as set forth in this Agreement and the other Transaction Documents. 

        In
the event of any ambiguity or conflict arising between the terms of this Agreement and those of the Orasense Memorandum of Association and Bye-Laws, the terms of this
Agreement shall prevail. 

        No
provision of this Agreement shall be construed so as to negate, modify or affect in any way the provisions of any other agreement between any of the Parties unless specifically
referred to, and solely
to the extent provided herein. In the event of a conflict between the provisions of this Agreement and the provisions of the License Agreements, the terms of the License Agreements shall prevail. 

        24.16    Successors:    This Agreement shall be binding upon and inure to the benefit of the Parties hereto, their
successors and permitted assigns. 

[Signature
Page Follows] 

25

        IN WITNESS WHEREOF, the Parties hereto have executed this Agreement on the day first set forth above. 

	

 	

 	
 	

SIGNED
	

 	

 	
 	

BY:	

/s/  KEVIN INSLEY      

	

 	

 	
 	

for and on behalf of

ELAN CORPORATION, PLC
	

in the presence of:	

/s/  DEBBIE BURYJ      
	
 	

 	

 
	

 	

 	
 	

SIGNED
	

 	

 	
 	

BY:	

/s/  DEBBIE BURYJ      

	

 	

 	
 	

for and on behalf of

ELAN INTERNATIONAL SERVICES, LTD.
	

in the presence of:	

/s/  KEVIN INSLEY      
	
 	

 	

 
	

 	

 	
 	

SIGNED
	

 	

 	
 	

BY:	

/s/  B. LYNNE PARSHALL      

	

 	

 	
 	

for and on behalf of

ISIS PHARMACEUTICALS, INC.
	

in the presence of:	

/s/  GRANTLAND E. BRYCE      
	
 	

 	

 
	

 	

 	
 	

SIGNED
	

 	

 	
 	

BY:	

/s/  E.C.J      

	

 	

 	
 	

for and on behalf of

ORASENSE LTD.
	

in the presence of:	

/s/  ILLEGIBLE      
	
 	

 	

 

SCHEDULE 1  

 ORASENSE COLLABORATION INTELLECTUAL PROPERTY  

        [***] 

SCHEDULE 2  

 RESEARCH PLAN(1)  

        [***]

	(1)
	Promptly
following the Effective Date, the Management Committee shall clarify the Research Plan as necessary to further detail the objectives of Orasense through the end of the
Research Term. 

Table 1. 2002 Oral Clinical Studies  

        [***]

BUDGET  

        [***]

ORASENSE BUDGET ASSUMPTIONS  

        [***]

QuickLinks

AMENDED AND RESTATED SUBSCRIPTION, JOINT DEVELOPMENT AND OPERATING AGREEMENT ELAN CORPORATION, PLC ELAN INTERNATIONAL SERVICES, LTD. ISIS PHARMACEUTICALS, INC. AND ORASENSE LTD. October 24, 2002

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00045-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00045-of-00352.parquet"}]]